var title_f5_41_5776="Tracheal diverticulum CT";
var content_f5_41_5776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheal diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan demonstrates a tracheal diverticulum originating from the right posterolateral wall of the trachea at the thoracic inlet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5776=[""].join("\n");
var outline_f5_41_5776=null;
var title_f5_41_5777="Plastibell procedure";
var content_f5_41_5777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Technique for performing circumcision using a Plastibell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 470px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) An incision is made in the top of the foreskin.",
"    <br>",
"     (B) The Plastibell is placed over the head of the penis, and the foreskin is pulled over the Plastibell.",
"     <br>",
"      (C) A suture is tied around the foreskin over the tying groove in the Plastibell. Excess skin beyond the suture is trimmed away. The Plastibell falls off in three to seven&nbsp;days.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Mabis Healthcare. The Plastibell Circumcision Device&reg; is a Registered Trademark of Mabis Healthcare.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5777=[""].join("\n");
var outline_f5_41_5777=null;
var title_f5_41_5778="Lyme disease treatment";
var content_f5_41_5778=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Lyme disease treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/41/5778/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5778/contributors\" id=\"au2858\">",
"       Linden Hu, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/41/5778/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5778/contributors\" id=\"se1447\">",
"       Allen C Steere, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/41/5778/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5778/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?5/41/5778?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LYME DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Lyme disease is the most common tick-borne illness in the United States and Europe. Lyme disease is caused by an infection with the bacteria Borrelia burgdorferi, which are carried by deer ticks. The bacteria are transmitted when a tick bites a person.",
"    </p>",
"    <p>",
"     In most people, treatment with antibiotics is very effective at eliminating symptoms, preventing complications of the disease, and curing the infection. Some symptoms improve rapidly with this treatment, whereas other symptoms gradually improve over weeks to months.",
"    </p>",
"    <p>",
"     This topic review discusses the treatment of Lyme disease. Separate topic reviews discuss what to do after a tick bite to prevent Lyme disease and the symptoms and diagnosis of Lyme disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"      \"Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"      \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"      \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about Lyme disease is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"      \"Epidemiology of Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"      \"Clinical manifestations of Lyme disease in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"      \"Diagnosis of Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"      \"Evaluation of a tick bite for possible Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"      \"Treatment of Lyme disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"      \"Prevention of Lyme disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      LYME DISEASE TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H326648745\">",
"     <span class=\"h2\">",
"      General principles",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics are the primary treatment for Lyme disease, and almost all patients recover after antibiotic treatment. The recommended treatment for Lyme disease varies depending upon the stage of disease and the types of symptoms. The rate of recovery may also vary depending upon the specific symptoms and recovery may take weeks to months after finishing antibiotic treatment.",
"    </p>",
"    <p>",
"     In about 10 to 15 percent of individuals with early Lyme disease, substances released by the dying bacteria cause a brief worsening of symptoms (called a Jarisch-Herxheimer reaction). This reaction occurs within 24 hours after starting antibiotics, continues for a day or so, and then resolves. Antibiotic therapy should not be stopped if this reaction develops, but should instead continue as originally planned.",
"    </p>",
"    <p>",
"     There is no evidence that the Lyme bacteria are resistant to any of the antibiotics commonly used to treat the infection. In rare cases, additional therapy beyond the recommended doses may be used for brief periods of time (typically one month). However there is",
"     <strong>",
"      no",
"     </strong>",
"     evidence that additional treatment with any antibiotic results in improvement of slowly resolving symptoms. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"      \"Treatment of Lyme disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Early localized Lyme disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Early localized Lyme disease (the erythema migrans rash, with or without flu-like symptoms) is treated with oral antibiotics, usually doxycycline, amoxicillin, or cefuroxime, taken daily. Doxycycline is given for 10 to 21 days, and amoxicillin and cefuroxime are given for 14 to 21 days.",
"    </p>",
"    <p>",
"     Antibiotics prevent worsening of the disease and may decrease the duration and severity of symptoms. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"      \"Musculoskeletal manifestations of Lyme disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Early disseminated Lyme disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;When Lyme disease is recognized after it has moved from the tick bite site to other locations, the recommended treatments may be either oral or intravenous antibiotics. Oral antibiotics are used for cases that are considered less serious. These include cases of multiple skin lesions, nerve involvement (such as facial palsy) in which the symptoms are limited to nerves that do not involve the brain or spinal cord, and mild cases of inflammation of the heart (typically causing slight delays in conduction of electrical signals from one part of the heart to the other). For cases of nerve involvement such as facial palsy, a spinal tap may be required to test the cerebrospinal fluid (CSF) for evidence of infection before deciding whether to treat with oral or intravenous antibiotics.",
"    </p>",
"    <p>",
"     More serious manifestations including meningitis (inflammation of the lining of the brain and spinal cord) and more advanced forms of heart block with moderate to severe delays in conduction are usually treated with intravenous therapy. For meningitis, usually the entire course of antibiotic is given intravenously, whereas for heart block, patients are generally monitored in hospital and given intravenous antibiotics initially. A temporary pacemaker may be required for patients with complete heart block resulting in a very slow heartbeat. When the heart block has improved, patients are often changed to oral antibiotics. For patients with multiple symptoms, the treatment used is dictated by the most serious manifestation. Treatment with intravenous antibiotics is typically recommended for 10 to 28 days (most commonly 14 days).",
"    </p>",
"    <p>",
"     Intravenous (IV) therapy is usually started in a healthcare provider's office or emergency department. It can be continued at home and monitored by a visiting or home health nurse. Patients receiving home intravenous therapy should watch for symptoms of infection or inflammation at the site of the IV line (pain, redness, and swelling) and symptoms of blood clots in the vein (pain and swelling in the arm or armpit). Because of the risks associated with intravenous antibiotics, some clinicians may chose to use oral antibiotics even for more serious manifestations of disease in some patients where the risk of intravenous therapy is elevated. It has not been proven that the use of intravenous antibiotics results in faster or more complete improvement of symptoms even in severe cases of meningitis and heart block. In European cases of Lyme disease, oral antibiotics appear to be equivalent to intravenous antibiotics for meningitis, but this has not been established for Lyme disease in the US.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Late Lyme disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Manifestations of late Lyme disease include arthritis and neurologic conditions.",
"    </p>",
"    <p>",
"     In most individuals, the arthritis of late Lyme disease resolves with oral antibiotic therapy given for 28 days; intravenous antibiotics are recommended only if the arthritis does not improve with oral treatment. However, in some adults and children, arthritis persists after antibiotic therapy.",
"    </p>",
"    <p>",
"     Arthritis that lingers after antibiotic therapy may require therapies used for other types of arthritis, such as hydroxychloroquine",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     synovectomy (surgical removal of the joint lining). More information about these treatments is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"      \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Neurologic conditions associated with late Lyme disease are treated with intravenous antibiotics, usually ceftriaxone or cefotaxime, given daily for two to four weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Post-Lyme disease syndromes",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, symptoms such as headache, fatigue, and joint pain do not resolve immediately after treatment is completed. In addition, some patients develop pain or fatigue after a gap of several weeks to months after antibiotic treatment of Lyme disease. These symptoms usually resolve gradually over time. Taking more antibiotics does not improve symptoms or shorten the course of post-Lyme symptoms.",
"    </p>",
"    <p>",
"     Chronic Lyme disease is another term that is used to describe symptoms of pain, fatigue, and difficulty thinking clearly that occur after antibiotic treatment of Lyme disease. There are currently no strict criteria for defining chronic Lyme disease, and no evidence that antibiotics beyond the currently recommended amounts improve symptoms. Because the symptoms are often non-specific and can overlap with many other diseases, it is important to ensure that there are no other potential causes of the symptoms that may be more amenable to therapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      CAN I GET LYME DISEASE AGAIN?",
"     </span>",
"    </p>",
"    <p>",
"     After being infected with and treated for",
"     <strong>",
"      early",
"     </strong>",
"     Lyme disease, it is possible to become infected with Lyme disease again. However, there has never been a case of re-infection with Lyme disease in a person who has had",
"     <strong>",
"      late",
"     </strong>",
"     Lyme disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      IS LYME DISEASE TREATMENT NECESSARY AFTER A TICK BITE?",
"     </span>",
"    </p>",
"    <p>",
"     Several factors must be taken into consideration when deciding if antibiotic treatment is necessary after a tick bite to prevent Lyme disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"      \"Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"      \"Evaluation of a tick bite for possible Lyme disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PREVENTING LYME DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     You can take steps to prevent infection with Lyme disease. This is discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"      \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784890215\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3704961\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/2/22562?source=see_link\">",
"      Patient information: Rocky Mountain spotted fever (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3704978\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"      Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"      Lyme carditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"      Prevention of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"      Treatment of Lyme disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/lymedisease.html\">",
"      www.nlm.nih.gov/medlineplus/lymedisease.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/lymeDisease/\">",
"      www3.niaid.nih.gov/topics/lymeDisease/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A review of Chronic Lyme Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/topics/lymeDisease/understanding/Pages/chronic.aspx\">",
"      www.niaid.nih.gov/topics/lymeDisease/understanding/Pages/chronic.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncidod/dvbid/lyme/\">",
"      www.cdc.gov/ncidod/dvbid/lyme/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lyme Disease Foundation, Inc.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aldf.com/faq.shtml\">",
"      www.aldf.com/faq.shtml",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?5/41/5778/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?5/41/5778?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5778/abstract/1\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5778/abstract/2\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5778/abstract/3\">",
"      Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med 2003; 348:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5778/abstract/4\">",
"      Piesman J, Eisen L. Prevention of tick-borne diseases. Annu Rev Entomol 2008; 53:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f5_41_5778=[""].join("\n");
var outline_f5_41_5778=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LYME DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           LYME DISEASE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           CAN I GET LYME DISEASE AGAIN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           IS LYME DISEASE TREATMENT NECESSARY AFTER A TICK BITE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PREVENTING LYME DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f5_41_5779="Erythromycin and benzoyl peroxide: Drug information";
var content_f5_41_5779=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin and benzoyl peroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/61/34772?source=see_link\">",
"    see \"Erythromycin and benzoyl peroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benzamycin&reg;;",
"     </li>",
"     <li>",
"      Benzamycin&reg; Pak",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14225984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benzamycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acne: Topical: Apply twice daily, morning and evening.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F166707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, topical: Erythromycin 30 mg and benzoyl peroxide 50 mg per g (23 g, 47 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Benzamycin&reg;: Erythromycin 30 mg and benzoyl peroxide 50 mg per g (47 g) [contains alcohol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Benzamycin&reg; Pak: Erythromycin 30 mg and benzoyl peroxide 50 mg per 0.8 g packet (60s) [supplied with diluent containing alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15517723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin should be clean and dry before applying. For external use only; avoid applying to inside nose, mouth, eyes, and mucous membranes. Wash hands before and after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzamycin&reg; Pak: Mix right before each use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical control of acne vulgaris",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15517126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Also see Erythromycin (Topical) monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dry skin (3% to 8%), urticaria (3%), pruritus (2% to 3%), burning (1% to 3%), erythema (1% to 3%), stinging (1% to 3%), photosensitivity (1%), oiliness, peeling, skin discoloration, skin tenderness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blepharitis (&le;2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15517118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to erythromycin, benzoyl peroxide, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5207388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleaching effects: May bleach hair or colored fabric.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Skin irritation: Discontinue use if severe skin irritation or redness occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Stop the drug if significant diarrhea occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Topical acne products: Use concomitant topical acne therapy with caution; cumulative irritancy may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For external use only; avoid contact with mucous membranes and eyes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Also see Erythromycin (Topical) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F166698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benzamycin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-3% (46.6 g): $369.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benzoyl Peroxide-Erythromycin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-3% (23.3 g): $58.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (BenzamycinPak External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-3% (60): $230.66",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benzac Eritromicina (BR);",
"     </li>",
"     <li>",
"      Benzac Kombi (CO);",
"     </li>",
"     <li>",
"      Benzac Plus (CR, DO, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Benzamycin (AR, BE, GR, MX, MY, PH, SG, TR);",
"     </li>",
"     <li>",
"      Erimicin (AR, CN, PY, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8735 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5779=[""].join("\n");
var outline_f5_41_5779=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166710\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166701\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166707\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166702\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166693\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166683\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15517723\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166695\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15517126\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15517118\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5207388\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299283\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166688\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166689\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287240\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166704\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287242\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166698\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539855\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166697\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8735|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/61/34772?source=related_link\">",
"      Erythromycin and benzoyl peroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_41_5780="ECG strip sinus tachycardia";
var content_f5_41_5780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing sinus tachycardia at a rate of 150 beats/min",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the difficulty in separating the P waves from the T waves in the standard leads. The P waves are most evident in lead V1 (arrow) where the terminal negativity suggests left atrial enlargement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5780=[""].join("\n");
var outline_f5_41_5780=null;
var title_f5_41_5781="Spondylolysis";
var content_f5_41_5781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spondylolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique radiographs in patients with spondylolysis reveal the defect at the pars interarticularis as a crack or collar on the neck of the \"Scotty dog.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smith JA, Hu SS. Management of spondylolysis and spondylolsisthesis in the pediatric and adolescent population. Orthop Clin North Am 1999; 30:487. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5781=[""].join("\n");
var outline_f5_41_5781=null;
var title_f5_41_5782="Midpalmar space abscess";
var content_f5_41_5782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Midpalmar space abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A midpalmar space abscess is characterized by loss of the normal palmar concavity as shown in the photograph. The long and ring fingers assume a partially flexed posture and there is pain on passive extension of these fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5782=[""].join("\n");
var outline_f5_41_5782=null;
var title_f5_41_5783="Diagnosis and outcome of first trimester growth delay";
var content_f5_41_5783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and outcome of first trimester growth delay",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5783/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5783/contributors\">",
"     Joan M Mastrobattista, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5783/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5783/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5783/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5783/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5783/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/41/5783/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the widespread use of ultrasound in early pregnancy, first trimester growth was thought to be uniform and under genetic control. Differences in fetal growth rates were not believed to manifest until the second half of pregnancy. However, these beliefs were challenged after analysis of data from thousands of first trimester ultrasound examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Early delay in fetal growth has been documented in pregnancies with precise gestational age dating, and appears to be predictive of subsequent adverse perinatal outcomes, such as fetal aneuploidy, growth restriction, and preterm birth.",
"   </p>",
"   <p>",
"    In this discussion, the term \"fetus\" will be used regardless of gestational age, even though \"embryo\" is the biological term for early human life (ie, implantation through eight weeks postconception) and \"fetus\" is the biological term for human intrauterine life thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF FIRST TRIMESTER GROWTH DELAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of growth delay is based upon fetal size that is smaller than expected. Thus, it is crucial to have accurate information on the fetus' gestational age and the normal size range for fetuses of that age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pitfalls in determining gestational age",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Use of last menstrual period",
"    </span>",
"    &nbsp;&mdash;&nbsp;When clinicians date a pregnancy based on menstrual weeks (menstrual age), the first trimester of pregnancy is defined as the time interval beginning on the first day of the last menstrual period (LMP) and ending 13 and",
"    <span class=\"nowrap\">",
"     0/7ths",
"    </span>",
"    weeks later. However, this calculation can lead to errors in assessment of gestational age and, in turn, estimated delivery date (EDD) because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many women do not have regular 28-day cycles and thus do not ovulate (or conceive) on day 14 of the cycle. The difference between the observed and expected size of",
"      <span class=\"nowrap\">",
"       embryos/fetuses",
"      </span>",
"      is thus biased towards smaller than expected measurements since the timing of ovulation is skewed to the second half of the cycle.",
"     </li>",
"     <li>",
"      Early pregnancy bleeding or recent use of hormonal contraceptives may lead to an incorrect assumption of the date of the last menstrual period.",
"     </li>",
"     <li>",
"      Some women are uncertain of the date of their LMP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Use of mean sac diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean sac diameter (MSD) is the average internal diameter of the gestational sac and may be utilized to determine gestational age when an embryo is not identified, but this measurement is less accurate than crown rump length measurements for gestational dating [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Use of crown rump length",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is consistent high quality evidence supporting measurement of crown rump length (CRL) as the best method for gestational dating [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/7-22\">",
"     7-22",
"    </a>",
"    ]. Once CRL can be measured, it should be used to estimate gestational age, rather than the mean sac diameter or an average of mean sac diameter and CRL. Gestational age assessment by ultrasound is most accurate when the CRL is measured between 6 and 10 weeks of gestation since there is less biologic variation and linear growth at that time. Interestingly, the growth rate in the first trimester does not appear to be linear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. There appears to be a change in growth rate between 9 and 10 weeks of gestation. The 9- to 10-week mark signifies the ending of the embryonic period and the beginning of the fetal period with a shift from organogenesis to growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRL early in gestation is visualized better with transvaginal sonography (TVS) than with transabdominal sonography (TAS), but the transvaginal approach is not more accurate for determining gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. TVS is also more useful in",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    women.",
"   </p>",
"   <p>",
"    The CRL should represent the longest length of the fetus, excluding the limbs and yolk sac. It is determined by placing calipers at the outer edge of the cephalic pole and the outer edge of the",
"    <span class=\"nowrap\">",
"     embryonic/fetal",
"    </span>",
"    rump. For optimum accuracy in dating pregnancies, we recommend that three independent CRL measurements be obtained and then averaged [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the ultrasound equipment is purchased, it comes with a choice of programs to calculate gestational age based on the biometry measurements obtained during an examination. We, like many other practices, use the Robinson tables for these calculations. One equation that performs well for calculating gestational age from CRL is [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/9,26\">",
"     9,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;gestational age (days) = (8.052)(CRL in",
"    <span class=\"nowrap\">",
"     mm)(1/2)",
"    </span>",
"    + 23.73",
"   </p>",
"   <p>",
"    The reported accuracy of CRL for estimation of gestational age depends upon the method used for validation (eg, LMP, known date of conception) and the gestational age when the measurement was obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/7,9,10,12-21\">",
"     7,9,10,12-21",
"    </a>",
"    ]. Early and late first trimester CRL measurements (less than 9 mm and greater than 70 mm) are less precisely correlated with a specific gestational age so there is a wider confidence interval (CI) around the gestational age estimate at these times [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/8-10,13,27\">",
"     8-10,13,27",
"    </a>",
"    ]. For this reason, some experts use biparietal diameter (BPD) to estimate gestational age after 10 weeks of gestation, but there is no consensus on this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/11,12,16,24,28\">",
"     11,12,16,24,28",
"    </a>",
"    ]. In our practice, we use CRL for the majority of",
"    <span class=\"nowrap\">",
"     embryo/fetuses",
"    </span>",
"    in the first trimester. As the gestational age progresses, the CRL lengthens, the fetus curls up, and it is often more difficult to get a straight line measurement of the CRL due to its contour. For this reason, measurement of the BPD or FL may be used to determine gestational age in some late first trimester fetuses. We start using a combination of BPD, head circumference, abdominal circumference, and femur length to calculate gestational age at 14 weeks.",
"   </p>",
"   <p>",
"    The 95% CI for the gestational age estimate can be derived by using a constant error of &plusmn;8 percent (2 standard deviations) of the estimate or by reporting variability in terms of specific days (&plusmn;2 to &plusmn;11 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/10\">",
"     10",
"    </a>",
"    ]. Clinically, a practical approach is to use the sonographically derived gestational age to calculate EDD if it differs from that calculated using the LMP by more than seven days (some practices use five to seven days) in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/5\">",
"     5",
"    </a>",
"    ]. The variability of predicting gestational age increases as pregnancy progresses. Using a constant error of &plusmn;8 percent of the estimate throughout the first trimester is also an option. We re-date pregnancies in the first trimester if the CRL differs by more than seven days compared to menstrual dates.",
"   </p>",
"   <p>",
"    Factors other than pregnancy duration may affect the accuracy of CRL for estimating gestational age, but the available evidence is inconclusive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trimester, the CRL of twins and triplets does not appear to differ significantly from that of singletons of the same gestational age [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/7,29\">",
"       7,29",
"      </a>",
"      ]. However, the fetuses in a multiple gestation often have different CRLs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/30\">",
"       30",
"      </a>",
"      ]. Just as in singletons, the gestation should be re-dated in the first trimester if the CRL differs by more than one week compared to the menstrual dates. However, if there is discrepancy in the size of the gestations and the pregnancy needs to be re-dated, we recommend using the smaller CRL to establish the gestational age, and then getting a follow-up scan in two weeks to assess interval growth.",
"     </li>",
"     <li>",
"      Fetal gender may have an effect. Some studies have reported that the CRL of females is smaller than the CRL of males [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/15\">",
"       15",
"      </a>",
"      ], although this has not been demonstrated consistently [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethnicity does not appear to affect CRL [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Timing of ovulation and implantation affect CRL: a long ovulation to implantation interval (or late implantation) can result in a smaller than expected CRL, independent of growth rate [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/33\">",
"       33",
"      </a>",
"      ]. Late implantation has been associated with an increased risk of miscarriage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK OF ANEUPLOIDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an association between a small CRL measurement and aneuploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. The two largest series illustrating this relationship are described below; however, both of these studies were limited by the small number of fetuses with specific aneuploidies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of pregnancies that underwent chorionic villus sampling at 9 to 13 weeks of gestation, the",
"      <span class=\"nowrap\">",
"       observed/expected",
"      </span>",
"      CRL ratio of 144 aneuploid fetuses was compared with the",
"      <span class=\"nowrap\">",
"       observed/expected",
"      </span>",
"      CRL ratio of 440 euploid anatomically normal matched control fetuses for evidence of CRL shortening [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/34\">",
"       34",
"      </a>",
"      ]. Expected values of CRL were based on LMP and obtained from regression equations generated from a separate normal group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fetuses &le;12 weeks of gestation with",
"      <span class=\"nowrap\">",
"       observed/expected",
"      </span>",
"      CRL ratio &le;0.82 had a significant increase in risk of aneuploidy (OR 4.30, 95% CI 2.32-7.96).",
"     </li>",
"     <li>",
"      A short CRL in the first trimester defined as expected CRL minus observed CRL &ge;14 mm was also associated with increased aneuploidy risk (OR 9.04, 95% CI 3.26-28.67). Using the threshold of expected minus observed CRL of &ge;14 mm, the positive predictive value for aneuploidy detection was 71.4 percent.",
"     </li>",
"     <li>",
"      The mean",
"      <span class=\"nowrap\">",
"       observed/expected",
"      </span>",
"      CRL ratio for fetuses with trisomy 18, 13, and 21 was 0.8, 0.9, and 1, respectively. Only fetuses with trisomy 21 did not have significantly shortened CRLs compared to euploid fetuses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another study of pregnancies undergoing fetal karyotyping by amniocentesis or chorionic villus sampling at 10 to 13 weeks of gestation, the CRLs of 135 chromosomally abnormal fetuses were compared with the CRLs of 700 chromosomally normal fetuses [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/35\">",
"       35",
"      </a>",
"      ]. Compared with normal fetuses, the median CRL of fetuses with trisomy 18 was significantly reduced, but no significant reduction was noted in fetuses with trisomy 21, trisomy 13, and other aneuploidies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DISCORDANT TWINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10572773\">",
"    <span class=\"h2\">",
"     Aneuploidy risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be a relationship between CRL discordance in twin gestations and aneuploidy. In a study of twins with CRL 45 to 84 mm, trisomy 18 and triploidy were diagnosed in the two cases with significant CRL discordance (difference in CRL between the larger and smaller twin of 17.3 and 16 mm, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If one CRL is small in a twin gestation, we assess amniotic fluid distribution and chorionicity. We also perform an early survey of the anatomy, and usually repeat the study within two weeks. Depending on the sonographic appearance (visually reduced amniotic fluid, fetal anomaly such as cystic hygroma or anencephaly), we offer the patient first trimester genetic screening (combined test consisting of hCG, PAPP-A, and nuchal translucency) or definitive testing (chorionic villus sampling, genetic amniocentesis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10572784\">",
"    <span class=\"h2\">",
"     Risk of pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discordance in CRL may be a factor predictive of adverse outcome of twin pregnancy, but the use of different thresholds of discordance and different exclusion criteria (eg, anomalous twins, aneuploid twins, monochorionic twins) among studies precludes making definite conclusions. As an example, in a study of 231 dichorionic twin pregnancies assessed ultrasonographically at 6 to 10 weeks gestation, 81 percent",
"    <span class=\"nowrap\">",
"     (163/201)",
"    </span>",
"    of pregnancies with intertwin CRL discordance &lt;20 percent resulted in two live births [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/38\">",
"     38",
"    </a>",
"    ]. The dual live birth rate fell to 37 percent",
"    <span class=\"nowrap\">",
"     (11/30)",
"    </span>",
"    with CRL discordancy &ge;20 percent. Dual survival rates were lower when discordancy in gestational sac diameter was &ge;30 percent. However, another study that included 420 monochorionic and 1735 dichorionic twin gestations found CRL discordance to have poor predictive value in detecting adverse perinatal outcomes and that chorionicity was the factor that independently contributed to determining mortality, not CRL discordance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RISK OF OTHER ADVERSE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most discrepancies between LMP and early ultrasound-based gestational age are attributable to errors in menstrual dating, these differences may reflect early growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/40\">",
"     40",
"    </a>",
"    ]. Poor growth in the first trimester may be due to suboptimal intrauterine environment (including disorders of placentation); however, it may also represent a constitutionally small fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small gestational sac size (MSD minus CRL &lt;5 mm), also described as first trimester oligohydramnios, is associated with an increased risk of pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Additionally, a CRL deficit below that expected for gestational age, especially if it exceeds two standard deviations, is associated with an increased risk of miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. The etiology may be aneuploidy or placental dysfunction.",
"   </p>",
"   <p>",
"    Several studies have reported an association between first trimester growth restriction and delivery of a low birth weight or small for gestational age (SGA) infant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/4,5,47-51\">",
"     4,5,47-51",
"    </a>",
"    ], although other studies have not confirmed this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/52\">",
"     52",
"    </a>",
"    ]. Infants who are of low birth weight or SGA at birth are at increased risk of a variety of perinatal, neonatal, childhood, and even adult complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between first trimester fetal size and pregnancy outcome was illustrated in a prospective cohort study involving 15 centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/5\">",
"     5",
"    </a>",
"    ]. The study population consisted of 975 singleton pregnancies from women who conceived as the result of assisted reproductive techniques and who delivered a live born infant without karyotypic or congenital anomalies. Fetuses with CRLs corresponding to a gestational age of 10 weeks 3 days and 13 weeks 6 days were included.",
"   </p>",
"   <p>",
"    The main finding of the study was that the size of the fetus in the first trimester was significantly associated with birth weight: for each one-day increase in the observed size of the fetus compared with the expected size, birth weight increased by 28.2 grams and pregnancy length increased by 0.42 days. Half of the correlation was due to the effect of first trimester size on pregnancy length, and the other half was due to fetal growth in the second half of pregnancy. Additionally, the risk of delivering an SGA infant was inversely related to first trimester growth.",
"   </p>",
"   <p>",
"    These findings suggest that pregnancy duration and complications of late pregnancy may result from conditions occurring very early in pregnancy, and are often determined before the initial prenatal visit. Postnatal effects have not been studied extensively; however, one large study found that first trimester fetal growth delay was associated with compensatory postnatal growth acceleration until age 2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5783/abstract/51\">",
"     51",
"    </a>",
"    ]. Further investigation to define these relationships is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of growth delay is based upon",
"      <span class=\"nowrap\">",
"       embryonic/fetal",
"      </span>",
"      size that is smaller than expected for gestational age. Thus, it is crucial to have accurate information on the fetus' gestational age and the normal range for crown rump length (CRL) for fetuses of that age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis of first trimester growth delay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gestational age assessment is most accurate when the crown rump length (CRL) is measured between 6 and 10 weeks of gestation since there is less biologic variation and linear growth at that time. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis of first trimester growth delay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There appears to be an association between small CRL and aneuploidy. However, small CRL can also be due to inaccurate menstrual dates. Obtaining a follow-up scan in two weeks is helpful to assess interval growth. Continued lag in size is worrisome for impending demise or aneuploidy. If a significant fetal growth delay is present, genetic counseling and testing may be offered in the first or second trimester. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk of aneuploidy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most discrepancies between last menstrual period and early ultrasound-based gestational age are attributable to errors in menstrual dating, these differences may reflect early growth restriction. Early growth restriction appears to be associated with increased risks of delivery of a low birth weight or small for gestational age infant. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk of other adverse outcomes'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, there is still a paucity of data regarding how this information can be used to change pregnancy management. In our ultrasound laboratory, if the CRL measurement lags menstrual dating by more than seven days in a well-dated first trimester pregnancy (earlier ultrasound, assisted-reproductive technology), we suggest a repeat evaluation in two weeks. If the growth lag continues into the second trimester and is unexplained, we suggest interval growth ultrasounds at two- to four-week intervals.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/1\">",
"      Salomon LJ, Bernard JP, Duyme M, et al. Revisiting first-trimester fetal biometry. Ultrasound Obstet Gynecol 2003; 22:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/2\">",
"      Smith GC. First trimester origins of fetal growth impairment. Semin Perinatol 2004; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/3\">",
"      Deter RL, Buster JE, Casson PR, Carson SA. Individual growth patterns in the first trimester: evidence for difference in embryonic and fetal growth rates. Ultrasound Obstet Gynecol 1999; 13:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/4\">",
"      Smith GC, Smith MF, McNay MB, Fleming JE. First-trimester growth and the risk of low birth weight. N Engl J Med 1998; 339:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/5\">",
"      Bukowski R, Smith GC, Malone FD, et al. Fetal growth in early pregnancy and risk of delivering low birth weight infant: prospective cohort study. BMJ 2007; 334:836.",
"     </a>",
"    </li>",
"    <li>",
"     AIUM practice guidelines for the performance of obstetric ultrasound examinations. AIUM, Laurel, MD, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/7\">",
"      Rossavik IK, Torjusen GO, Gibbons WE. Conceptual age and ultrasound measurements of gestational sac and crown-rump length in in vitro fertilization pregnancies. Fertil Steril 1988; 49:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/8\">",
"      Robinson HP. Sonar measurement of fetal crown-rump length as means of assessing maturity in first trimester of pregnancy. Br Med J 1973; 4:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/9\">",
"      Robinson HP, Fleming JE. A critical evaluation of sonar \"crown-rump length\" measurements. Br J Obstet Gynaecol 1975; 82:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/10\">",
"      Hadlock FP, Shah YP, Kanon DJ, Lindsey JV. Fetal crown-rump length: reevaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US. Radiology 1992; 182:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/11\">",
"      Lasser DM, Peisner DB, Vollebergh J, Timor-Tritsch I. First-trimester fetal biometry using transvaginal sonography. Ultrasound Obstet Gynecol 1993; 3:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/12\">",
"      Bovicelli L, Orsini LF, Rizzo N, et al. Estimation of gestational age during the first trimester by real-time measurement of fetal crown-rump length and biparietal diameter. J Clin Ultrasound 1981; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/13\">",
"      Drumm JE, Clinch J, MacKenzie G. The ultrasonic measurement of fetal crown-rump length as a method of assessing gestational age. Br J Obstet Gynaecol 1976; 83:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/14\">",
"      Nelson LH. Comparison of methods for determining crown-rump measurement by real-time ultrasound. J Clin Ultrasound 1981; 9:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/15\">",
"      Pedersen JF. Fetal crown-rump length measurement by ultrasound in normal pregnancy. Br J Obstet Gynaecol 1982; 89:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/16\">",
"      Selbing A. Gestational age and ultrasonic measurement of gestational sac, crown-rump length and biparietal diameter during first 15 weeks of pregnancy. Acta Obstet Gynecol Scand 1982; 61:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/17\">",
"      MacGregor SN, Tamura RK, Sabbagha RE, et al. Underestimation of gestational age by conventional crown-rump length dating curves. Obstet Gynecol 1987; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/18\">",
"      Vollebergh JH, Jongsma HW, van Dongen PW. The accuracy of ultrasonic measurement of fetal crown-rump length. Eur J Obstet Gynecol Reprod Biol 1989; 30:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/19\">",
"      Evans J. Fetal crown-rump length values in the first trimester based upon ovulation timing using the luteinizing hormone surge. Br J Obstet Gynaecol 1991; 98:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/20\">",
"      Silva PD, Mahairas G, Schaper AM, Schauberger CW. Early crown-rump length. A good predictor of gestational age. J Reprod Med 1990; 35:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/21\">",
"      Koornstra G, Wattel E, Exalto N. Crown-rump length measurements revisited. Eur J Obstet Gynecol Reprod Biol 1990; 35:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/22\">",
"      Kustermann A, Zorzoli A, Spagnolo D, Nicolini U. Transvaginal sonography for fetal measurement in early pregnancy. Br J Obstet Gynaecol 1992; 99:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/23\">",
"      Dickey RP, Gasser RF. Ultrasound evidence for variability in the size and development of normal human embryos before the tenth post-insemination week after assisted reproductive technologies. Hum Reprod 1993; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/24\">",
"      Grisolia G, Milano K, Pilu G, et al. Biometry of early pregnancy with transvaginal sonography. Ultrasound Obstet Gynecol 1993; 3:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/25\">",
"      Lohr PA, Reeves MF, Creinin MD. A comparison of transabdominal and transvaginal ultrasonography for determination of gestational age and clinical outcomes in women undergoing early medical abortion. Contraception 2010; 81:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/26\">",
"      Grange G, Pannier E, Goffinet F, et al. Dating biometry during the first trimester: accuracy of an every-day practice. Eur J Obstet Gynecol Reprod Biol 2000; 88:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/27\">",
"      Goldstein SR, Wolfson R. Endovaginal ultrasonographic measurement of early embryonic size as a means of assessing gestational age. J Ultrasound Med 1994; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/28\">",
"      Hadlock FP. Sonographic estimation of fetal age and weight. Radiol Clin North Am 1990; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/29\">",
"      Bhide A, Sankaran S, Sairam S, et al. Relationship of intertwin crown-rump length discrepancy to chorionicity, fetal demise and birth-weight discordance. Ultrasound Obstet Gynecol 2009; 34:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/30\">",
"      Salomon LJ, Cavicchioni O, Bernard JP, et al. Growth discrepancy in twins in the first trimester of pregnancy. Ultrasound Obstet Gynecol 2005; 26:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/31\">",
"      Becker S, Ural S, Fehm T, Bienstock J. Fetal gender and sonographic assessment of crown-rump length: implications for multifetal pregnancy reduction. Ultrasound Obstet Gynecol 2004; 24:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/32\">",
"      Parker AJ, Davies P, Newton JR. Assessment of gestational age of the Asian fetus by the sonar measurement of crown-rump length and biparietal diameter. Br J Obstet Gynaecol 1982; 89:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/33\">",
"      Mahendru AA, Daemen A, Everett TR, et al. Impact of ovulation and implantation timing on first-trimester crown-rump length and gestational age. Ultrasound Obstet Gynecol 2012; 40:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/34\">",
"      Bahado-Singh RO, Lynch L, Deren O, et al. First-trimester growth restriction and fetal aneuploidy: the effect of type of aneuploidy and gestational age. Am J Obstet Gynecol 1997; 176:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/35\">",
"      Kuhn P, Brizot ML, Pandya PP, et al. Crown-rump length in chromosomally abnormal fetuses at 10 to 13 weeks' gestation. Am J Obstet Gynecol 1995; 172:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/36\">",
"      Leelapatana P, Garrett WJ, Warren PS. Early growth retardation in the first trimester: is it characteristic of the chromosomally abnormal fetus? Aust N Z J Obstet Gynaecol 1992; 32:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/37\">",
"      Drugan A, Johnson MP, Isada NB, et al. The smaller than expected first-trimester fetus is at increased risk for chromosome anomalies. Am J Obstet Gynecol 1992; 167:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/38\">",
"      Papaioannou GI, Syngelaki A, Maiz N, et al. Prediction of outcome in dichorionic twin pregnancies at 6-10 weeks' gestation. Am J Obstet Gynecol 2011; 205:348.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/39\">",
"      D'Antonio F, Khalil A, Dias T, Thilaganathan B. Crown-Rump Length Discordance And Adverse Perinatal Outcome In Twins: The Stork Multiple Pregnancy Cohort. Ultrasound Obstet Gynecol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/40\">",
"      Morin I, Morin L, Zhang X, et al. Determinants and consequences of discrepancies in menstrual and ultrasonographic gestational age estimates. BJOG 2005; 112:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/41\">",
"      Bromley B, Harlow BL, Laboda LA, Benacerraf BR. Small sac size in the first trimester: a predictor of poor fetal outcome. Radiology 1991; 178:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/42\">",
"      Dickey RP, Olar TT, Taylor SN, et al. Relationship of small gestational sac-crown-rump length differences to abortion and abortus karyotypes. Obstet Gynecol 1992; 79:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/43\">",
"      Papaioannou GI, Syngelaki A, Maiz N, et al. Ultrasonographic prediction of early miscarriage. Hum Reprod 2011; 26:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/44\">",
"      Reljic M. The significance of crown-rump length measurement for predicting adverse pregnancy outcome of threatened abortion. Ultrasound Obstet Gynecol 2001; 17:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/45\">",
"      Choong S, Rombauts L, Ugoni A, Meagher S. Ultrasound prediction of risk of spontaneous miscarriage in live embryos from assisted conceptions. Ultrasound Obstet Gynecol 2003; 22:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/46\">",
"      Mukri F, Bourne T, Bottomley C, et al. Evidence of early first-trimester growth restriction in pregnancies that subsequently end in miscarriage. BJOG 2008; 115:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/47\">",
"      Smith GC, Stenhouse EJ, Crossley JA, et al. Early-pregnancy origins of low birth weight. Nature 2002; 417:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/48\">",
"      Leung TY, Sahota DS, Chan LW, et al. Prediction of birth weight by fetal crown-rump length and maternal serum levels of pregnancy-associated plasma protein-A in the first trimester. Ultrasound Obstet Gynecol 2008; 31:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/49\">",
"      Mercer BM, Merlino AA, Milluzzi CJ, Moore JJ. Small fetal size before 20 weeks' gestation: associations with maternal tobacco use, early preterm birth, and low birthweight. Am J Obstet Gynecol 2008; 198:673.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/50\">",
"      Thorsell M, Kaijser M, Almstr&ouml;m H, Andolf E. Expected day of delivery from ultrasound dating versus last menstrual period--obstetric outcome when dates mismatch. BJOG 2008; 115:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/51\">",
"      Mook-Kanamori DO, Steegers EA, Eilers PH, et al. Risk factors and outcomes associated with first-trimester fetal growth restriction. JAMA 2010; 303:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5783/abstract/52\">",
"      Kazemier BM, Kleinrouweler CE, Oudijk MA, et al. Is short first-trimester crown-rump length associated with spontaneous preterm birth? Ultrasound Obstet Gynecol 2012; 40:636.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 410 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-118.195.65.248-F33F7FC12B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5783=[""].join("\n");
var outline_f5_41_5783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF FIRST TRIMESTER GROWTH DELAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pitfalls in determining gestational age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Use of last menstrual period",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Use of mean sac diameter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Use of crown rump length",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK OF ANEUPLOIDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DISCORDANT TWINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10572773\">",
"      Aneuploidy risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10572784\">",
"      Risk of pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RISK OF OTHER ADVERSE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_41_5784="Intimate partner violence: Epidemiology and health consequences";
var content_f5_41_5784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intimate partner violence: Epidemiology and health consequences",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5784/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5784/contributors\">",
"     Amy Weil, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5784/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5784/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/41/5784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H86601624\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence (IPV) is a serious, preventable public health problem affecting more than 32 million Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1\">",
"     1",
"    </a>",
"    ]. In countries around the world, 10 to 69 percent of women report physical assault by an intimate partner at some time in their life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"intimate partner violence\" describes actual or threatened psychological, physical, or sexual harm by a current or former partner or spouse. IPV can occur among heterosexual or same-sex couples and does not require sexual intimacy.",
"   </p>",
"   <p>",
"    Abusive relationships often begin as verbal and emotional abuse but may become physical. Most women who are victims of physical aggression experience multiple episodes of aggression over time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/3\">",
"     3",
"    </a>",
"    ]. While \"intimate terrorism,\" in which a passive victim in an abusive relationship lives in constant fear for the next episode of abuse, is the classic IPV paradigm, IPV may be",
"    <span class=\"nowrap\">",
"     mutual/bidirectional",
"    </span>",
"    (\"situational violence\") or may take the form of \"violence resistance,\" in which the identified victim fights back [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying psychological dynamic in most types of violence is power and control of the victim by the abuser, as shown in a model of physical and sexual violence. The assumption that, within a heterosexual relationship, all violence is initiated by men and directed towards women is not correct, although women are far more likely to experience IPV than men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the epidemiology and health consequences of intimate partner violence. Screening and diagnosis of intimate partner violence is discussed separately, as is management for patients in whom intimate partner violence is diagnosed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link\">",
"     \"Intimate partner violence: Diagnosis and screening\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=see_link\">",
"     \"Intimate partner violence: Intervention and patient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601631\">",
"    <span class=\"h1\">",
"     TYPES OF INTIMATE PARTNER VIOLENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main types of intimate partner violence (IPV) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Psychological/emotional",
"      </span>",
"     </li>",
"     <li>",
"      Physical",
"     </li>",
"     <li>",
"      Sexual",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical violence occurs less frequently than other forms of IPV and is usually preceded by other forms of control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/6\">",
"     6",
"    </a>",
"    ]. Experiencing abuse in one domain may increase the risk of other types of abuse. In one study, 68 percent of physically abused women were also sexually abused [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two patterns of violence between couples have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/2\">",
"     2",
"    </a>",
"    ]. &ldquo;Battering&rdquo; involves severe and escalating violence with terrorization and increasingly controlling behavior. &ldquo;Common couple violence&rdquo; is a more moderate form of IPV in which violence occurs occasionally, triggered by frustration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anger.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601638\">",
"    <span class=\"h2\">",
"     Psychological/emotional violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological/emotional",
"    violence involves trauma to the victim caused by threats of actions or coercive tactics. Threats of physical or sexual violence use words, gestures, or weapons to communicate an intent to cause physical harm, injury, disability, or death.",
"   </p>",
"   <p>",
"    Psychological violence may include humiliation, control over what a person can and cannot do, withholding information, isolating the victim from friends and family, or denying access to money or other basic resources. This type of IPV may also include stalking, repeated behavior that causes victims to experience a high level of fear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601645\">",
"    <span class=\"h2\">",
"     Physical violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical violence is the intentional use of physical force with the potential to cause harm, injury, disability, or death. Physical violence includes scratching, pushing, shoving, throwing, grabbing, biting, strangulating, shaking, slapping, punching, or burning. It may also include using a weapon, restraints, or one's size or strength against another person.",
"   </p>",
"   <p>",
"    Physical violence varies in frequency and severity, ranging from one hit to chronic severe battering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601652\">",
"    <span class=\"h2\">",
"     Sexual violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual violence may occur in the context of intimate partners, including date rape, but may also occur between strangers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sexual violence may be divided into three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of physical force to compel a person to engage in a sexual act against his or her will, whether or not the act is completed",
"     </li>",
"     <li>",
"      An attempted or completed sex act involving a person who is unable to understand the nature of the act, or unable to communicate unwillingness because of illness, disability, the influence of alcohol or other drugs, or because of intimidation or pressure",
"     </li>",
"     <li>",
"      Abusive sexual contact",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601659\">",
"    <span class=\"h2\">",
"     International perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) includes IPV as a part of a larger problem referred to as \"gender-based violence\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/8\">",
"     8",
"    </a>",
"    ]. Gender-based violence also encompasses rape by strangers, female genital mutilation, sexual harassment in the workplace, selective malnutrition of girls, and human trafficking. These problems are based in the family, the community, and the political system (",
"    <a class=\"graphic graphic_table graphicRef86332 \" href=\"UTD.htm?15/31/15868\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This model is limited by the assumption that perpetration occurs only from men to women and that only women are victims. It also focuses more on physical and sexual, rather than emotional, types of IPV. However, it does provide a framework that may be useful in understanding how IPV occurs in societies worldwide. It also emphasizes the role of society and community, rather than individual factors, in promoting and perpetuating violence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601666\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601674\">",
"    <span class=\"h2\">",
"     United States data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small percentage of intimate partner violence (IPV) episodes are reported, so that epidemiologic data are estimates only. Among women in the United States, it has been estimated that about 20 percent of sexual assaults, 25 percent of physical assaults, and 50 percent of stalking episodes are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1\">",
"     1",
"    </a>",
"    ]. Even fewer IPV incidents against men are reported.",
"   </p>",
"   <p>",
"    Despite acknowledged underreporting, one national study in the United States found that 29 percent of women and 22 percent of men admitted ever experiencing psychological, physical, or sexual IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/9\">",
"     9",
"    </a>",
"    ]. Women were more likely to acknowledge physical or sexual abuse, and less likely to report isolated verbal abuse than men. The Behavioral Risk Factor Surveillance System 2005, an anonymous telephone survey of more than 70,000 US adults, found that 23.6 percent of women and 11.5 percent of men reported a lifetime threatened or completed physical or sexual IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/10\">",
"     10",
"    </a>",
"    ]. In the same survey, 1.4 percent of women and 0.7 percent of men reported victimization within the past year. In another US survey based on 16,507 interviews completed in 2010, 18.3 percent of women and 1.4 percent of men reported being raped (completed or attempted forced penetration) at some time in their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly 4.8 million incidents of IPV related to physical assault and rape occur each year among women ages 18 and older in the United States (US) and 2.9 million occur among men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2008, the rate of IPV was 4.3 per 1000 females age 12 or older and 0.8 per 1000 males [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/12\">",
"     12",
"    </a>",
"    ]. Most assaults are relatively minor and consist of pushing, grabbing, shoving, slapping, and hitting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1\">",
"     1",
"    </a>",
"    ]. However, IPV was a cause of an estimated 2340 deaths in 2007, with 70 percent occurring in women and 30 percent in men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IPV accounted for 20 percent of nonfatal violence against women in 2001 and 3 percent against men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/13\">",
"     13",
"    </a>",
"    ]. The prevalence of emotional IPV is thought to be higher than physical or sexual abuse, but is harder to measure. Estimates indicate more than 1 million women and 371,000 men are stalked by intimate partners each year in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601681\">",
"    <span class=\"h3\">",
"     Homicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007, IPV accounted for 14 percent of all homicides in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/12\">",
"     12",
"    </a>",
"    ]. Trends suggest that the number of homicides attributed to IPV has been decreasing.",
"   </p>",
"   <p>",
"    One study found that 44 percent of women murdered by their intimate partner had visited an emergency department within two years of the homicide, and 93 percent had at least one injury visit, suggesting ongoing violence occurred before the homicide presenting an opportunity for providers to intervene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601688\">",
"    <span class=\"h2\">",
"     Worldwide data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) sponsored a survey of over 24,000 women in 10 countries (15 sites) to investigate physical and sexual IPV in women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;Lifetime prevalence of physical or sexual IPV ranged from 15 to 75 percent; the prevalence was 50 to 75 percent in 6 of the 15 sites. In almost all sites, the risk of partner-related physical or sexual violence far exceeded the risk of other violence. Physical violence only was the most common pattern of IPV, although 30 to 56 percent of women in most sites experienced both physical and sexual violence.",
"   </p>",
"   <p>",
"    In another report from WHO, rates of reported assault by a partner in the past month in some countries were as high as 52 percent, with physical assault part of a continuing pattern of abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/2\">",
"     2",
"    </a>",
"    ]. Various types of abuse coexist, with overlap between psychological, physical, and sexual abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601695\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Domestic violence often begins or increases during pregnancy and the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The relationship between domestic violence and pregnancy is illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one review of the obstetrical literature, physical abuse occurred during 7 to 20 percent of pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/18\">",
"       18",
"      </a>",
"      ]. A United States national survey found that between 4 and 8 percent of pregnant women reported being abused at least once during the pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with an unintended pregnancy have a higher risk (threefold greater in one study) of physical abuse compared to those whose pregnancy was planned [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/20\">",
"       20",
"      </a>",
"      ]. Of note, one-half of pregnancies in the United States are unintended [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abused pregnant women have a threefold higher risk of being victims of",
"      <span class=\"nowrap\">",
"       attempted/completed",
"      </span>",
"      homicide than non-abused women with similar demographic characteristics [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601702\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence (IPV) cuts across gender, racial, ethnic, and socioeconomic boundaries. Although no individual has absolute immunity from involvement with IPV, certain groups are at greater risk for IPV victimization or perpetration. Some risk factors, such as childhood physical or sexual victimization, increase the likelihood for both IPV victimization and perpetration.",
"   </p>",
"   <p>",
"    Contributing risk factors, while associated with a greater likelihood of IPV victimization or perpetration, are not themselves causes of IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/3\">",
"     3",
"    </a>",
"    ]. According to an ecological model of IPV, a combination of individual, relationship, community, and societal factors contributes to the risk of being a victim or perpetrator of IPV. Understanding these multilevel factors can help identify various points to target preventive interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601709\">",
"    <span class=\"h2\">",
"     Risk factors for victimization",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601717\">",
"    <span class=\"h3\">",
"     Individual factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior history of IPV [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/3,14\">",
"       3,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Female [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Young age (&lt;24) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/16,23\">",
"       16,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      At-risk alcohol use or drug use",
"     </li>",
"     <li>",
"      High-risk sexual behavior",
"     </li>",
"     <li>",
"      Witnessing or experiencing violence as a child [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      History of depression [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Less educated [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unemployment or being below the poverty line [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      For women in the US, being American",
"      <span class=\"nowrap\">",
"       Indian/Alaska",
"      </span>",
"      Native or African American [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601724\">",
"    <span class=\"h3\">",
"     Relationship factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Couples with income, educational, or job status disparities",
"     </li>",
"     <li>",
"      Dominance and control of the relationship by a male",
"     </li>",
"     <li>",
"      Excessive jealousy or possessive behavior",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601731\">",
"    <span class=\"h3\">",
"     Community and societal factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poverty and associated factors (eg, overcrowding)",
"     </li>",
"     <li>",
"      Lack of institutions or community norms that shape social interactions",
"     </li>",
"     <li>",
"      Weak community sanctions against IPV (eg, police unwilling to intervene)",
"     </li>",
"     <li>",
"      Traditional gender norms (eg, women should stay at home and not enter workforce, should be submissive)",
"     </li>",
"     <li>",
"      In some countries, notions of",
"      <span class=\"nowrap\">",
"       male/family",
"      </span>",
"      honor and female chastity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601739\">",
"    <span class=\"h2\">",
"     Risk factors for perpetration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the factors associated with risk for IPV victimization are also factors for perpetration. A few are of particular relevance to perpetrators:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure to childhood violence [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unresolved posttraumatic stress disorder, especially related to returning veterans [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recent job loss or instability [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Substance abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601746\">",
"    <span class=\"h2\">",
"     Male victims",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although women are more likely to be victims than men, one study in an urban emergency department suggests that the dynamics present when males are victims are similar to those of female victims [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/27\">",
"     27",
"    </a>",
"    ]. Risk factors for male victims were young age, being single, African American, and uninsured. The most common forms of assault were slapping, grabbing, and shoving (60.6 percent). Thirty-seven percent of cases involved a weapon; 7 percent of victims described being forced to have sex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601753\">",
"    <span class=\"h1\">",
"     HEALTH EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many common physical and psychological health conditions are associated with intimate partner violence (IPV) and can be exacerbated by the context of violence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/10\">",
"     10",
"    </a>",
"    ]. General conclusions about the impact of IPV on health issues are [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The severity of abuse correlates with the impact on physical and mental health",
"     </li>",
"     <li>",
"      The impact of multiple episodes and types of abuse over time is cumulative",
"     </li>",
"     <li>",
"      The effect of abuse persists long after the abuse has terminated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Behavioral Risk Factor Surveillance System, a large telephone survey in the United States, correlated violence reported in the prior year with patient medical records [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/10\">",
"     10",
"    </a>",
"    ]. Compared with non-abused women, women who reported IPV in the past year were at significantly increased risk for multiple medical and psychosocial problems. While IPV may lead to direct physical injury, \"functional\" physical ailments (eg, chronic pain syndromes, gastrointestinal disorders) are a more common physical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/3\">",
"     3",
"    </a>",
"    ]. The health consequences of IPV are similar comparing same-sex and opposite-sex victims [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601760\">",
"    <span class=\"h2\">",
"     Physical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical consequences of IPV depend upon the severity and frequency of abuse. At least 42 percent of women and 20 percent of men who were physically assaulted since age 18 sustained injuries during their most recent victimization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1\">",
"     1",
"    </a>",
"    ]. Most injuries were minor, including scratches, bruises, and welts. More serious injuries include knife wounds and broken bones. Signs of strangulation may be present and include red eyes, neck swelling, petechiae, and ecchymoses on the neck; however, no visible injury is seen in the majority of cases of attempted strangulation (",
"    <a class=\"graphic graphic_picture graphicRef86280 \" href=\"UTD.htm?43/30/44527\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to the direct injury consequences of the assault itself, multiple chronic medical complaints are associated with IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/3,29,30\">",
"     3,29,30",
"    </a>",
"    ]. Data from a random sample of women in a large US health plan, comparing women who reported IPV in the past year and women who reported never having experienced IPV, indicate the following relative risks (RR) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/29\">",
"     29",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Headaches (RR 1.57)",
"     </li>",
"     <li>",
"      Back pain and other musculoskeletal pain (RR 1.61-1.71)",
"     </li>",
"     <li>",
"      Chest pain (RR 1.53)",
"     </li>",
"     <li>",
"      Gynecological disorders including menstrual disorders, pelvic pain, and dyspareunia (RR 1.84)",
"     </li>",
"     <li>",
"      Sexually transmitted diseases, including",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      (RR 3.15)",
"     </li>",
"     <li>",
"      Gastrointestinal disorders (reflux) (RR 1.76)",
"     </li>",
"     <li>",
"      Urinary tract infection (RR 1.79)",
"     </li>",
"     <li>",
"      Acute respiratory infection (RR 1.33)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601767\">",
"    <span class=\"h2\">",
"     Pregnancy morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A national survey revealed that experiencing IPV in the year prior to pregnancy increased the likelihood of high blood pressure or edema; vaginal bleeding; severe nausea, vomiting, or dehydration; kidney infection or urinary tract infection; preterm delivery; low-birth weight infant; and an infant requiring intensive care unit care [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/31\">",
"     31",
"    </a>",
"    ]. Other pregnancy complications, such as abruption, fetal fractures, premature labor, and perinatal death, have also been associated with IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/32\">",
"     32",
"    </a>",
"    ]. The risk for postpartum depression is two to threefold in women who have experienced psychological or physical abuse during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601774\">",
"    <span class=\"h2\">",
"     Psychological",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical and sexual violence is typically accompanied by emotional or psychological abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/1,34\">",
"     1,34",
"    </a>",
"    ]. A cross-sectional study of women in Australia found that women who reported at least one type of gender-based violence (GBV) (which may include IPV with physical violence, rape, sexual assault,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stalking) were over four times more likely to report a severe current mental disorder than women who did not identify GBV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychological consequences for victims of IPV include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety disorder (RR 2.73)",
"     </li>",
"     <li>",
"      Depression (RR 3.26)",
"     </li>",
"     <li>",
"      Family and social problems (RR 4.96)",
"     </li>",
"     <li>",
"      Substance abuse (RR 5.89)",
"     </li>",
"     <li>",
"      Eating disorders &nbsp;",
"     </li>",
"     <li>",
"      Posttraumatic stress disorder (PTSD)",
"     </li>",
"     <li>",
"      Sleep disorders",
"     </li>",
"     <li>",
"      Suicide attempts",
"     </li>",
"     <li>",
"      Low self-esteem",
"     </li>",
"     <li>",
"      Fear of intimacy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of female victims of IPV, PTSD was found in 75 percent of the sample and major depression (MDD) in 54 percent; comorbid PTSD and MDD were common and led to greater maladaptive issues than either diagnosis alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/35\">",
"     35",
"    </a>",
"    ]. Physical violence is often associated with sexual violence, which increases the likelihood that a patient will present with PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of IPV and PTSD has also been associated with biologic effects, including changes in morning cortisol levels and cellular components of the immune system, with potential impact on cardiovascular and immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/32,36\">",
"     32,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601781\">",
"    <span class=\"h2\">",
"     Effect on children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may become injured during IPV incidents between their parents, either in the act of defending a parent or unintentionally.",
"   </p>",
"   <p>",
"    IPV increases the relative risk for child maltreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one study, children of abused mothers were 57 times more likely to have been harmed, compared with children of non-abused mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Adverse Childhood Events Study has shown that adverse childhood events including abuse and neglect, but especially witnessing partner violence among parents, are linked to adult poor health [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/36\">",
"     36",
"    </a>",
"    ]. It is hypothesized these childhood events lead to maladaptive coping behaviors and changes in stress response at the level of the hypothalamic-pituitary-adrenal axis that can adversely impact general health and increase the risk for posttraumatic stress disorder (PTSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link&amp;anchor=H3#H3\">",
"     \"Childhood exposure to intimate partner violence\", section on 'Effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H86601795\">",
"     'Risky health behaviors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601788\">",
"    <span class=\"h2\">",
"     Disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cross sectional study in a family medicine clinic revealed a twofold increase in the incidence of disability in those exposed to IPV, compared to those without an IPV history [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/42\">",
"     42",
"    </a>",
"    ]. Disability was associated with heart or circulatory disease, back pain, chronic pain, arthritis, nerve system damage, asthma, emphysema, and depression or another mental illness.",
"   </p>",
"   <p>",
"    In addition to disability as a potential consequence of IPV, persons with disabilities, and intellectual disability (mental retardation) in particular, may be at greater risk for IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/43\">",
"     43",
"    </a>",
"    ]. As well, persons with disabilities are more likely to experience difficulty in accessing services, when needed, for reporting and intervening in IPV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601795\">",
"    <span class=\"h2\">",
"     Risky health behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPV is associated with a variety of negative health behaviors that further increase health risks. The more severe the violence, the stronger its relationship to negative health behaviors among victims [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5784/abstract/30,44\">",
"     30,44",
"    </a>",
"    ]. Such adverse health behaviors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-risk sexual behavior: Decreased condom use; early sexual debut; choosing unhealthy sexual partners; multiple sex partners; trading sex for food, money, or drugs",
"     </li>",
"     <li>",
"      Using or abusing harmful substances: Cigarette smoking, alcohol",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      drug abuse, driving after drinking alcohol",
"     </li>",
"     <li>",
"      Unhealthy diet-related behaviors: Fasting, vomiting, abusing diet pills, overeating",
"     </li>",
"     <li>",
"      Nonadherence to health recommendations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86601802\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"intimate partner violence\" (IPV) describes actual or threatened psychological, physical, or sexual harm by a current or former partner or spouse. IPV can occur among heterosexual or same-sex couples and does not require sexual intimacy. (See",
"      <a class=\"local\" href=\"#H86601624\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three main types of intimate partner violence are psychological, physical, and sexual. Psychological violence relates to threats of actions or coercive tactics, including stalking. Physical violence is the intentional use of physical force with the potential to cause harm, injury, disability, or death. Sexual violence includes use of force to compel a sexual act, a sexual act with a person who is unable to consent, or abusive sexual contact. (See",
"      <a class=\"local\" href=\"#H86601631\">",
"       'Types of intimate partner violence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexual and physical IPV assaults are greatly underreported. A US survey found that 24 percent of women and 12 percent of men acknowledged a lifetime threatened or completed physical or sexual IPV. Worldwide, lifetime prevalence of physical or sexual IPV in women ranges from 15 to 75 percent. IPV was a factor in approximately 20 percent of US homicides with three-quarters of the victims being female. (See",
"      <a class=\"local\" href=\"#H86601666\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPV often begins or escalates during pregnancy. Other risk factors include being a young female, alcohol or drug use, less educated, family history or prior exposure to violence. (See",
"      <a class=\"local\" href=\"#H86601702\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPV is associated with an increased incidence of medical problems and pregnancy complications. IPV victims have significantly increased psychological illness, including major depression and posttraumatic stress disorder (PTSD). Additionally, IPV is associated with a variety of negative health behaviors including high risk sexual behavior, substance abuse, eating disorders, and nonadherence to health recommendations. (See",
"      <a class=\"local\" href=\"#H86601753\">",
"       'Health effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tjaden P, Thoennes N. Extent, nature, and consequences of intimate partner violence: findings from the National Violence Against Women Survey. Publication No. NCJ-181867, US Department of Justice, Washington, DC 2000.",
"    </li>",
"    <li>",
"     The World Health Organization. World report on violence and health. Chapter 4. Violence by intimate partners. file://www.who.int/violence_injury_prevention/violence/global_campaign/en/chap4.pdf (Accessed on August 07, 2011).",
"    </li>",
"    <li>",
"     Heise L, Garcia-Moreno C. Violence by intimate partners. In: World report on violence and health, Krug E, Dahlberg LL, Mercy JA, et al (Eds), World Health Organization, Geneva 2002.",
"    </li>",
"    <li>",
"     Intimate Partner Violence in  Practical Gynecology: A Guide for the Primary Care Physician, 2nd ed, Ryden J, Blumenthal PD, Charney P (Eds), American College of Physicans, 2009.",
"    </li>",
"    <li>",
"     Saltzman LE, Fanslow JL, McMahon PM, Shelley GA. Intimate Partner Violence Surveillance: Uniform Definitions and Recommended Data Elements (Version 1.0). Centers for Disease Control and Prevention. National Center for Injury Prevention and Control, Atlanta 2002. Available at: file://www.cdc.gov/ncipc/pub-res/ipv_surveillance/intimate.htm#Read (Accessed on June 20, 2012).",
"    </li>",
"    <li>",
"     Intimate Partner Violence. Masachusetts Medical Society Committee on Violence Intervention and Prevention. 5th Edition. file://www.massmed.org/AM/Template.cfm?Section=Home6&amp;CONTENTID=36015&amp;TEMPLATE=/CM/ContentDisplay.cfm (Accessed on August 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/7\">",
"      McFarlane J, Malecha A, Watson K, et al. Intimate partner sexual assault against women: frequency, health consequences, and treatment outcomes. Obstet Gynecol 2005; 105:99.",
"     </a>",
"    </li>",
"    <li>",
"     Ellsberg, M, Heise, L. Researching Violence Against Women: A Practical Guide for Researchers and Activists. World Health Organization/PATH, Washington, DC 2005. Available at: file://www.who.int/reproductivehealth/publications/violence/9241546476/en/ (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/9\">",
"      Coker AL, Davis KE, Arias I, et al. Physical and mental health effects of intimate partner violence for men and women. Am J Prev Med 2002; 23:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Adverse health conditions and health risk behaviors associated with intimate partner violence--United States, 2005. MMWR Morb Mortal Wkly Rep 2008; 57:113.",
"     </a>",
"    </li>",
"    <li>",
"     Black M, Basile K, Breidling M, et al. The National Intimate Partner and Sexual Violence Survey: 2010 summary report. Atlanta: National Center for Injury Prevention and control. Centers for Disease Control and Prevention, 2011. file://www.cdc.gov/violenceprevention/pdf/nisvs_executive_summary-a.pdf (Accessed on February 15, 2013).",
"    </li>",
"    <li>",
"     http:bjs.ojp.usdoj.gov/index.cfm?ty=tp&amp;tid=971#summary.",
"    </li>",
"    <li>",
"     Rennison C. Intimate partner violence 1993-2001. Publication no. NCJ-197838, Bureau of Justice Statistics; US Department of Justice, Washington, DC 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/14\">",
"      Crandall ML, Nathens AB, Kernic MA, et al. Predicting future injury among women in abusive relationships. J Trauma 2004; 56:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/15\">",
"      Garcia-Moreno C, Jansen HA, Ellsberg M, et al. Prevalence of intimate partner violence: findings from the WHO multi-country study on women's health and domestic violence. Lancet 2006; 368:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/16\">",
"      Hillard PJ. Physical abuse in pregnancy. Obstet Gynecol 1985; 66:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/17\">",
"      Stewart DE. Incidence of postpartum abuse in women with a history of abuse during pregnancy. CMAJ 1994; 151:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/18\">",
"      Gazmararian JA, Lazorick S, Spitz AM, et al. Prevalence of violence against pregnant women. JAMA 1996; 275:1915.",
"     </a>",
"    </li>",
"    <li>",
"     Tjaden P, Thoennes N. Full report of the prevalence, incidence, and consequences of violence against women: findings from the National Violence Against Women Survey. Publication no. NCJ-183781, US Department of Justice, Washington, DC 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/20\">",
"      Goodwin MM, Gazmararian JA, Johnson CH, et al. Pregnancy intendedness and physical abuse around the time of pregnancy: findings from the pregnancy risk assessment monitoring system, 1996-1997. PRAMS Working Group. Pregnancy Risk Assessment Monitoring System. Matern Child Health J 2000; 4:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/21\">",
"      Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/22\">",
"      McFarlane J, Campbell JC, Sharps P, Watson K. Abuse during pregnancy and femicide: urgent implications for women's health. Obstet Gynecol 2002; 100:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/23\">",
"      McCloskey LA, Lichter E, Ganz ML, et al. Intimate partner violence and patient screening across medical specialties. Acad Emerg Med 2005; 12:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/24\">",
"      Renner LM, Whitney SD. Risk factors for unidirectional and bidirectional intimate partner violence among young adults. Child Abuse Negl 2012; 36:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/25\">",
"      Lehrer JA, Buka S, Gortmaker S, Shrier LA. Depressive symptomatology as a predictor of exposure to intimate partner violence among US female adolescents and young adults. Arch Pediatr Adolesc Med 2006; 160:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/26\">",
"      Marshall AD, Panuzio J, Taft CT. Intimate partner violence among military veterans and active duty servicemen. Clin Psychol Rev 2005; 25:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/27\">",
"      Mechem CC, Shofer FS, Reinhard SS, et al. History of domestic violence among male patients presenting to an urban emergency department. Acad Emerg Med 1999; 6:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/28\">",
"      Blosnich JR, Bossarte RM. Comparisons of intimate partner violence among partners in same-sex and opposite-sex relationships in the United States. Am J Public Health 2009; 99:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/29\">",
"      Bonomi AE, Anderson ML, Reid RJ, et al. Medical and psychosocial diagnoses in women with a history of intimate partner violence. Arch Intern Med 2009; 169:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/30\">",
"      Plichta SB. Intimate partner violence and physical health consequences: policy and practice implications. J Interpers Violence 2004; 19:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/31\">",
"      Silverman JG, Decker MR, Reed E, Raj A. Intimate partner violence victimization prior to and during pregnancy among women residing in 26 U.S. states: associations with maternal and neonatal health. Am J Obstet Gynecol 2006; 195:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/32\">",
"      Dutton MA, Green BL, Kaltman SI, et al. Intimate partner violence, PTSD, and adverse health outcomes. J Interpers Violence 2006; 21:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/33\">",
"      Ludermir AB, Lewis G, Valongueiro SA, et al. Violence against women by their intimate partner during pregnancy and postnatal depression: a prospective cohort study. Lancet 2010; 376:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/34\">",
"      Rees S, Silove D, Chey T, et al. Lifetime prevalence of gender-based violence in women and the relationship with mental disorders and psychosocial function. JAMA 2011; 306:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/35\">",
"      Nixon RD, Resick PA, Nishith P. An exploration of comorbid depression among female victims of intimate partner violence with posttraumatic stress disorder. J Affect Disord 2004; 82:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/36\">",
"      Dube SR, Anda RF, Felitti VJ, et al. Exposure to abuse, neglect, and household dysfunction among adults who witnessed intimate partner violence as children: implications for health and social services. Violence Vict 2002; 17:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/37\">",
"      Appel AE, Holden GW. The co-occurrence of spouse and physical child abuse: a review and appraisal. J Fam Psychology 1998; 12:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/38\">",
"      Taylor CA, Guterman NB, Lee SJ, Rathouz PJ. Intimate partner violence, maternal stress, nativity, and risk for maternal maltreatment of young children. Am J Public Health 2009; 99:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/39\">",
"      Parkinson GW, Adams RC, Emerling FG. Maternal domestic violence screening in an office-based pediatric practice. Pediatrics 2001; 108:E43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/40\">",
"      McAllister TW, Stein MB. Effects of psychological and biomechanical trauma on brain and behavior. Ann N Y Acad Sci 2010; 1208:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/41\">",
"      Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002; 346:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/42\">",
"      Coker AL, Smith PH, Fadden MK. Intimate partner violence and disabilities among women attending family practice clinics. J Womens Health (Larchmt) 2005; 14:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/43\">",
"      Hughes K, Bellis MA, Jones L, et al. Prevalence and risk of violence against adults with disabilities: a systematic review and meta-analysis of observational studies. Lancet 2012; 379:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5784/abstract/44\">",
"      Roberts TA, Klein JD, Fisher S. Longitudinal effect of intimate partner abuse on high-risk behavior among adolescents. Arch Pediatr Adolesc Med 2003; 157:875.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2789 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5784=[""].join("\n");
var outline_f5_41_5784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H86601802\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86601624\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86601631\">",
"      TYPES OF INTIMATE PARTNER VIOLENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601638\">",
"      Psychological/emotional violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601645\">",
"      Physical violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601652\">",
"      Sexual violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601659\">",
"      International perspective",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86601666\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601674\">",
"      United States data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86601681\">",
"      - Homicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601688\">",
"      Worldwide data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601695\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86601702\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601709\">",
"      Risk factors for victimization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86601717\">",
"      - Individual factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86601724\">",
"      - Relationship factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86601731\">",
"      - Community and societal factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601739\">",
"      Risk factors for perpetration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601746\">",
"      Male victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86601753\">",
"      HEALTH EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601760\">",
"      Physical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601767\">",
"      Pregnancy morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601774\">",
"      Psychological",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601781\">",
"      Effect on children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601788\">",
"      Disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86601795\">",
"      Risky health behaviors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86601802\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2789|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/30/44527\" title=\"picture 1\">",
"      Strangulation findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2789|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/31/15868\" title=\"table 1\">",
"      Manifestations of gender based violence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=related_link\">",
"      Intimate partner violence: Intervention and patient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_41_5785="Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)";
var content_f5_41_5785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5785/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5785/contributors\">",
"     Anna Nowak-Wgrzyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5785/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5785/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5785/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/41/5785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pollen-food allergy syndrome (PFAS) describes allergic reactions, usually limited to the oropharynx, which occur upon ingestion of certain fresh fruits, nuts, or vegetables in individuals who are sensitized to plant pollens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These reactions are a form of immunoglobulin E (IgE)-mediated immediate hypersensitivity. The causative allergens in these plant foods are homologous to pollen allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The disorder is also called \"pollen-food syndrome\" and &ldquo;pollen-associated food allergy syndrome&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral allergy syndrome (OAS) is a term used variably as a synonym of PFAS, or to describe just the isolated oropharyngeal symptoms caused by pollen-related foods. In this review, OAS is applied to isolated oropharyngeal symptoms.",
"   </p>",
"   <p>",
"    The symptoms of OAS result from contact urticaria of the oropharynx. Symptoms are usually limited to the mouth and throat and only observed with raw forms of the food because the causative allergens are rapidly inactivated by digestion and cooking, although this is not uniformly true. Systemic reactions, as well as reactions to cooked foods, are observed in a small proportion of patients.",
"   </p>",
"   <p>",
"    This topic review will present the pathogenesis of PFAS. The clinical manifestations, risk factors, diagnosis, and management of PFAS are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fruit and vegetable allergens are highly conserved and share varying degrees of homology with allergens from other fruits and vegetables as well as pollens; this structural and functional homology underlies the extensive cross-reactivity observed clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5003846\">",
"    <span class=\"h2\">",
"     Sensitization to pollen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitization to inhaled pollen proteins via the respiratory tract is believed to be the initial pathogenic event. The pollen-specific IgE generated by this mechanism then binds to the surface of mast cells and basophils throughout the body, including those in the oropharyngeal mucosa. Upon oral contact with a related food, these IgE molecules recognize homologous proteins in the food, triggering localized release of inflammatory mediators and the symptoms of OAS. In most cases, the allergens are subsequently destroyed in the stomach, limiting any further reaction.",
"   </p>",
"   <p>",
"    In support of the inciting role of pollen, studies suggest that oropharyngeal reactions caused by foods that are related to birch pollen (such as apple) are more prevalent in areas where birch trees are common, such as central and northern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, in birch-free Spain, allergy to apple presents differently; it is more often associated with systemic reactions (in &gt;35 percent of patients) and has been attributed to different allergens, suggesting a distinct pathogenic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/8\">",
"     8",
"    </a>",
"    ]. In vitro, dendritic cells from birch pollen-allergic donors exposed to Bet v 1 induced allergen-specific T-cell proliferation and Th2 polarization (IL-5, IL-13); in contrast exposure to celery Api g 1 significantly enhanced the production of IFN-&gamma; and downregulated IL-13 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALLERGENS IN PFAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conformational B-cell epitopes implicated in OAS and PFAS are sensitive to heat, acid, and digestive enzymes, and therefore usually cause reactions limited to the oropharynx. Freezing does not appear to inactivate these epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, the allergens responsible for isolated food allergy (in the absence of pollen sensitization) are typically resistant to both heat and digestion and therefore have a greater potential to cause systemic symptoms.",
"   </p>",
"   <p>",
"    Birch-allergic individuals appear to develop PFAS more commonly than those allergic to grass or weed pollens. The allergens causing birch-related OAS have been relatively well characterized, and most are either Bet v 1-cross-reactive antigens or profilins. Plane-allergic subjects in Spain were reported to have over a 50 percent rate of plant-food allergy, most frequently to hazelnut and peach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/11\">",
"     11",
"    </a>",
"    ]. In plane-allergic adults with peach allergy, the nsLTP Pla a 3 was shown to be a major allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/12\">",
"     12",
"    </a>",
"    ]. Much less is known about the allergens responsible for PFAS in grass- and weed-allergic patients, compared to those in tree pollen-allergic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Birch pollen-related allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary allergens causing PFAS in birch-sensitized patients are Bet v 1-cross-reactive antigens and profilins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bet v 1-cross-reactive antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bet v 1 is a major allergenic protein in birch tree (Betula verrucosa) pollen. Bet v 1 belongs to the family of the pathogenesis-related proteins 10 (PRP-10), which is important to plant defense [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Most PFAS in birch-allergic individuals is caused by proteins that cross-react with Bet v 1, including those in Rosacea fruits (apple, cherry, apricot, pear, plum) and Apiaceae vegetables (eg, celery, carrot) (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/15\">",
"     15",
"    </a>",
"    ]. Bet v 1 homologs include Mal d 1 (in apple), Pru av 1 (in cherry), Pru ar 1 (in apricot), Pyr c 1 (in pear), Api g 1 (in celery), and Dau c 1 (in carrot).",
"   </p>",
"   <p>",
"    Bet v 1- type allergenic epitopes are conformational in nature and depend on the intact tertiary protein folding. They are highly susceptible to heating and digestion and undergo prompt disintegration in the stomach. Such treatments destroy the IgE-binding capacity of these allergens, although the ability to activate allergen-specific T cells persists [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In some adults with atopic dermatitis and birch pollen allergy, ingestion of cooked birch pollen-related foods results in worsening of eczema [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/17\">",
"     17",
"    </a>",
"    ]. One could speculate that similar effects might occur in other conditions with T cell-mediated mechanisms, such as eosinophilic esophagitis, allergic rhinitis, or asthma. In addition, ingestion of cooked birch-pollen cross-reactive foods might drive perennially increased allergen-specific IgE levels in patients suffering from seasonal allergic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Profilins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first profilin identified was an allergen in birch pollen that was named Bet v 2; the profilins are now known to be ubiquitous cross-reactive plant allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/20\">",
"     20",
"    </a>",
"    ]. IgE of birch pollen-food allergic individuals cross-reacts with Bet v 2 homologous proteins from apple, pear, melon, carrot, celery, potato, and mugwort (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. Sensitization to profilins can be found in 10 to 30 percent of pollen-allergic patients and most likely occurs via respiratory tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ALLERGENS IN ISOLATED FRUIT/VEGETABLE ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When fruit or vegetable allergy develops",
"    <strong>",
"     in the absence",
"    </strong>",
"    of pollen allergy, patients may be sensitized to nonspecific lipid transfer proteins (nsLTPs) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. In general, sensitization to nsLTPs is associated with higher rates of systemic reactions. Recently, nsLTp in peanut (Ara h 9) has been identified as a new relevant allergen for patients in the Mediterranean region [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonspecific lipid transfer proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions to plant foods in patients sensitized to nsLTPs are more likely to be severe and systemic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/28\">",
"     28",
"    </a>",
"    ]. NsLTPs belong to the prolamin superfamily of plant proteins and are members of pathogenesis related proteins 14 (PRP-14). They have antifungal and antibacterial properties and are involved in plant defense [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/29\">",
"     29",
"    </a>",
"    ]. NsLTPs are abundant in the peel of plant foods. NsLTPs have been found to be major allergens in various foods (eg, peach Pru p 3, cherry Pru av 3, apple Mal d 3, hazelnut Cor a 8, orange Cit s 3, strawberry Fra a 3) and in pollen.",
"   </p>",
"   <p>",
"    These proteins are highly cross-reactive due to extensive sequence homology and are panallergens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Panallergens are structurally homologous and phylogenetically conserved allergenic proteins that are frequently responsible for IgE-mediated poly-sensitization and false-positive test results in subjects without clinical reactivity.",
"   </p>",
"   <p>",
"    NsLTPs are remarkably heat-stable, presumably due to 4 &alpha;-helices stabilized by 4 disulfide bonds. NsLTPs retain their allergenicity in processed foods, such as sterilized peach juice, cooked apple, beer, and fermented products, such as wine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. NsLTPs are also resistant to digestive enzymes (pepsin, trypsin) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensitization to nsLTPs is prevalent in the Mediterranean areas (eg, Spain and southern Italy, where birch trees do not grow) and uncommon in Central and Northern Europe (where birches are common) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is assumed that nsLTPs may sensitize both by inhalation and ingestion. In fact, nsLTPs are a minor allergen in subjects with plane pollen allergy without food allergy and a major allergen in subjects with reported food allergy to peach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/12\">",
"     12",
"    </a>",
"    ]. Sensitization via the gastrointestinal route may be more important in this type of allergy, considering the prevalence of this disorder in areas lacking birch trees. When T-cells were purified from peripheral blood and stimulated with natural peach nsLTP Pru p 3, they produced mainly Th2 cytokines and very little IL-10, unlike T-cells specific for other plant food and pollen allergens. The expression of gut homing integrin &beta;7 on Pru p 3-specific T-cells was comparable to that observed on peanut-specific T-cells and higher compared with that seen in different pollen-specific T-cells, suggesting gastrointestinal route of sensitization to nsLTP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ALLERGENS IN SPECIFIC FOODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific allergens have been identified in some plant foods that are associated with either oropharyngeal or systemic reactions. However, there is currently no way to discern which allergen an individual is sensitized to, outside of research settings. Thus, this information is presented to help clinicians understand the known associations between pollens and foods, and be aware of the foods that have been implicated in systemic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Apple",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apple allergen Mal d 1, a common cause of OAS, is a Bet v 1 homolog that shares 64 percent amino acid sequence similarity and common IgE epitopes with Bet v 1. A study utilized Bet v 1-Mal d 1 chimeric protein and showed that birch-allergic adults with PFAS to apple had significantly higher IgE reactivity to the Mal d 1 regions grafted on Bet v 1 than birch-allergic adults without PFAS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/40\">",
"     40",
"    </a>",
"    ]. This suggests that different B-cell epitopes may be important for the expression of PFAS to apple. Mal d 1 is highly unstable and can be disrupted by heating, processing, and digestion. In contrast, the nsLTP Mal d 3 is highly resistant to heating and retains the ability to bind IgE following heating at 90&ordm;C for 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/34,41\">",
"     34,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple reports documented that in the areas where birch trees are common, such as in central and northern Europe (Netherlands, Austria, northern Italy), allergic symptoms to apple are usually mild (&gt;90 percent report oral symptoms), and associated with birch pollen allergy and sensitization to Mal d 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/8,42\">",
"     8,42",
"    </a>",
"    ]. In contrast, in birch-free southern Europe (Spain), allergy to apple is more often severe (&gt;35 percent report systemic reactions) and associated with peach allergy and sensitization to the nsLTP Mal d 3.",
"   </p>",
"   <p>",
"    The content of these allergens in individual apples is highly variable and affected by the specific cultivar, ripeness at the time of harvesting, and duration and conditions of storage. Both Mal d 1 and Mal d 3 are expressed throughout fruit development and their levels increase with ripening. Certain apple cultivars were reported to contain less Mal d 1, such as Santana or Braeburn, compared with high Mal d 1 content in Golden Delicious and Jonagold. These differences were confirmed with prick skin testing and DBPCFC for Santana and Golden Delicious [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/42\">",
"     42",
"    </a>",
"    ]. Mal d 1 content was shown to increase during storage at 2&ordm;C and was higher in stored apples than in freshly picked apples [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hazelnut",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hazelnut contains allergens homologous to Cor a 1 and Bet v 1, the major allergens in hazel and birch pollens respectively, as well as profilins, Cor a 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/45\">",
"     45",
"    </a>",
"    ]. Other allergens, including heat-stable proteins below 10 kDa, and the lipid transfer protein, Cor a 8, may be responsible for systemic reactions to hazelnut [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Sensitization to Cor a 1 is highly prevalent in hazelnut-allergic patients from Western Europe",
"    <span class=\"nowrap\">",
"     (Switzerland/Denmark)",
"    </span>",
"    while sensitization to Cor a 8 is more common in patients from Spain. Sensitization to profilin Cor a 2 is detected in approximately 40 percent of the patients with hazelnut allergy regardless of geographic location [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Peanut",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanuts, even after roasting, can be another source of OAS in birch allergic patients (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ). In a series of 20 adult patients with birch pollen and peanut allergy who underwent DBPCFC to lightly roasted peanut flour, 60 percent developed only OAS, whereas 40 percent had additional systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/49\">",
"     49",
"    </a>",
"    ]. Specific IgE antibodies against the peanut allergen Ara h 8, homologous with birch Bet v 1, were detected in sera from 85 percent of subjects. Ara h 8 was partially disrupted by roasting and completely destroyed by gastric enzymes. These data suggest that peanuts may cause OAS in a subset of birch pollen allergic individuals. However, clinicians should be aware that the majority of peanut and tree nut allergic individuals react to non pollen-related stable proteins that result in more systemic and severe reactions. Thus, diagnosis of PFAS in subjects with peanut and or tree nut-induced oral symptoms should be made cautiously. We usually consider patients with peanut or tree nut allergy, even if symptoms have been limited to the oropharynx, to be at risk for more severe reactions and manage them accordingly (ie, prescribe self-injectable epinephrine and provide appropriate counseling). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Component Resolved Diagnostics technology that detects IgE sensitization to individual allergens may be used in the future to define the risk for more severe symptoms, such as detectable IgE antibodies to stable seed storage proteins , eg, Ara h 1, Ara h 2 a, and Ara h 3. Exclusive IgE sensitization to pollen-cross reactive Ara h 8 may be associated with mild oral symptoms and low risk for anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef79719 \" href=\"UTD.htm?12/47/13048\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link\">",
"     \"Future diagnostic tools for food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Celery",
"    </span>",
"    &nbsp;&mdash;&nbsp;OAS caused by celery tuber (celeriac) can be seen in patients who are sensitized only to birch (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ). Cross-reactivity between Bet v 1 and celery Api g 1 underlies this reaction. Systemic reactions to celery are also reported. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Celery-mugwort-spice syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Peach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peach is one of the most frequent causes of food allergy in Europe, both in the northern regions and in Mediterranean areas. Profilins are cross-reactive proteins in pollen and peach and are the likely cause of OAS, which is more common in central and northern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/50\">",
"     50",
"    </a>",
"    ]. In one report, up to 86 percent of patients with pollinosis reported isolated oropharyngeal symptoms in response to peach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peach allergy in the Mediterranean (eg, Spain) appears to be particularly prevalent and is associated with more systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/52\">",
"     52",
"    </a>",
"    ]. One Spanish study showed that 73 percent of peach-allergic patients did not have pollen allergy and these subjects reacted with anaphylaxis. Peach nsLTP (Pru p 3) was the responsible allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/30\">",
"     30",
"    </a>",
"    ]. By comparison, in a study of Spanish patients who had both peach allergy and pollinosis, the nsLTP Pla a 3, also found in the pollen of the plane tree, was a major allergen, and Pru p 3 was a minor allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cultural differences in food procurement may also contribute to the high rates of systemic peach reactions in Spain. Peach nsLTP is highly concentrated in the peach fuzz [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/53\">",
"     53",
"    </a>",
"    ]. When peaches are bought from small local farmers, as is typical in the Mediterranean, they typically have abundant fuzz. In contrast, when peaches are grown by large producers, the fruit is brushed and washed prior to packaging, and most of the peach fuzz is removed. Peaches in central and northern European countries are generally imported from large producers.",
"   </p>",
"   <p>",
"    Peach-allergic patients are frequently reactive to other related foods (",
"    <a class=\"graphic graphic_figure graphicRef79411 \" href=\"UTD.htm?9/46/9952\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/2,54\">",
"     2,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Carrot",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carrot-specific IgE antibodies can cross react with celery, watermelon, apiaceous spices (fennel, coriander, caraway, aniseed), and birch and mugwort pollens (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ). The responsible carrot allergens are Dau c 1 (a Bet v 1 homolog), carrot profilin, a Bet v 6 cross-reactive allergen, and cross-reactive carbohydrate determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case series of 20 patients with carrot allergy documented with DBPCFC to raw carrot, 16 patients developed OAS, three patients had additional symptoms outside the oropharynx, and one patient had no oral symptoms, but developed flushing, conjunctivitis, and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Celery-mugwort-spice syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Soybean",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soybean is a prominent cause of systemic food allergy in children; reactions are attributed to heat-stable proteins that induce sensitization via the gastrointestinal tract, such as seed storage proteins (legumins and vicilins). In adults, soybeans may cause OAS or systemic symptoms.",
"   </p>",
"   <p>",
"    One study examined 20 adults without previous reactions to soy who developed OAS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic symptoms following ingestion of a soy protein-containing food supplement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/58\">",
"     58",
"    </a>",
"    ]. IgE binding to Gly m 4 (previously called starvation-associated message 22 or SAM22) was demonstrated in the majority. Gly m 4 is homologous to Bet v 1.",
"   </p>",
"   <p>",
"    In another study, 22 birch-allergic adults with histories of soy reactions underwent DBPCFC, 10 patients experienced symptoms localized to the oral cavity, and six patients had a more severe reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/59\">",
"     59",
"    </a>",
"    ]. Gly m 4-specific IgE was found in all but one of the patients. The Gly m 4 content of foods was highly dependent on processing, and was lowest in unripe green soybeans and highest in ripe soybeans after three years of storage. Gly m 4 content of soybeans was reduced after 30 minutes of cooking. Among food products, Gly m 4 content was highest in dietary soy powder (used in foods such as protein energy bars), much lower in tofu and soy drink, and undetectable in fermented soy products, such as soy sauce and miso.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Kiwi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kiwi fruit has been reported to cause both OAS and severe systemic reactions and cross reactions with celery, rye, birch, mugwort, and timothy grass pollen, and latex (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major allergen specific for kiwi appears to be actinidin (Act c 1), a member of the cysteine protease family [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/62\">",
"     62",
"    </a>",
"    ]. Actinidin does not cross-react with pollen proteins, is assumed to cause sensitization via the gastrointestinal tract, and is associated with more severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/63\">",
"     63",
"    </a>",
"    ]. Bet v 1 homolog, Act d 8 and profilin, Act d 9 are important allergens in pollen-related kiwi allergy manifesting with less severe symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Melons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients reporting allergy to melons (Cucurbitaceae) (watermelon, cantaloupe, and honeydew) have weed pollen allergy (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ); melon allergic patients are often reactive to other related foods (avocado, banana, kiwi, and peach) (",
"    <a class=\"graphic graphic_figure graphicRef79411 \" href=\"UTD.htm?9/46/9952\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/1,64,65\">",
"     1,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Melon allergy can also arise from cross-reactivity with grass pollens. Clinical studies from a ragweed-free area showed that melon allergy still occurred mainly in patients with pollinosis, although Plantago and orchard grass pollens were the cross-reactive pollens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/1\">",
"     1",
"    </a>",
"    ]. Sera from 17 adults from Spain with oral symptoms to melons bound profilin Cuc m 2, and the majority also recognized profilins from timothy grass Phl p 12 and birch Bet v 2. The Cuc m 2 mimotope was defined and was almost identical to the sequences in Phl p 12 and Bet v 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/21\">",
"     21",
"    </a>",
"    ]. Allergy to zucchini, another plant in the Cucurbitaceae family, has been reported and confirmed with DBPCFCs with two of four patients having OAS. IgE-inhibition experiments showed cross-reactivity with the birch pollen profilin (Bet v 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SYNDROMES ASSOCIATED WITH SYSTEMIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain types of PFAS are associated with more severe reactions. Several of these have been recognized as specific syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Celery-mugwort-spice syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"celery-spice-mugwort syndrome\" is a potentially severe form of celery allergy seen in patients who are sensitized to both birch and mugwort. Patients may react to the Apiaceae family (carrot, caraway, parsley, fennel, coriander, fenugreek, cumin, dill, and aniseed), as well as paprika, pepper, mango, garlic, leek, and onion (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. This cross-reactivity is believed to be due to celery profilin (Api g 4), which is highly cross-reactive with profilins from both mugwort (Art v 4) and birch (Bet v 2), as well as latex Hev b 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/69\">",
"     69",
"    </a>",
"    ]. Some patients may also react to latex. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Latex-fruit syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with celery-mugwort sensitization had IgE antibodies that recognized heated celery extracts, in contrast to those with OAS to celery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, 46-kDa to 60-kDa bands cross-reacting with IgE against mugwort pollen extract have been described in celery and identified as cross-reactive carbohydrate determinants (CCDs) on glycoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients with reactions to cooked celery confirmed by DBPCFC were sensitized to profilin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CCDs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Mugwort-mustard syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients sensitized to mugwort (Artemisia vulgaris) may develop allergy to mustard and experience severe reactions. The responsible allergens have not been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Latex-fruit syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 to 50 percent of individuals who are allergic to natural rubber latex (NRL) show an associated hypersensitivity to some plant-derived foods, especially fresh fruits [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/72\">",
"     72",
"    </a>",
"    ]. In one series, over 50 percent of reported reactions to foods in latex-allergic individuals were anaphylactic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/73\">",
"     73",
"    </a>",
"    ]. An increasing number of plant foods, such as avocado, banana, chestnut, kiwi, peach, tomato, white potato, and bell pepper, have been associated with this syndrome (",
"    <a class=\"graphic graphic_figure graphicRef60713 \" href=\"UTD.htm?0/50/801\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5785/abstract/73-77\">",
"     73-77",
"    </a>",
"    ]. The allergens involved in the latex-fruit syndrome include hevein (Hev b 6.02), Hev b 7, and the panallergen profilin Hev b 8.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pollen-food allergy syndrome (PFAS) describes IgE-mediated allergic reactions, usually limited to the oropharynx, which occur upon ingestion of certain fresh fruits, nuts, vegetables, or spices, in individuals who are sensitized to plant pollens. The causative allergens in these plant foods are homologous to pollen allergens. The term oral allergy syndrome (OAS) is used in this review to describe PFAS reactions that are limited to the oropharynx. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenic mechanism begins in the respiratory tract with sensitization to inhaled pollens. Symptoms then result from oral contact with plant foods containing homologous allergens. In most cases, although not all, the allergens are subsequently destroyed in the stomach, limiting any further reaction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The allergens implicated in OAS and PFAS are sensitive to heat, acid, and digestive enzymes. The primary allergens causing PFAS in birch-sensitized patients are Bet v 1-cross-reactive antigens and profilins. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Allergens in PFAS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to the allergens that cause PFAS, the allergens responsible for isolated food allergy (in the absence of pollen sensitization) are typically resistant to both heat and digestion, and therefore have a greater potential to cause systemic symptoms. Sensitization is believed to occur through the gastrointestinal tract. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Allergens in isolated fruit/vegetable allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific allergens have been identified in some plant foods, which are associated with either oropharyngeal or systemic reactions. However, there is currently no way to discern which allergen an individual is sensitized to, outside of research settings. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Allergens in specific foods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Syndromes associated with systemic reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/1\">",
"      Rodriguez J, Crespo JF, Burks W, et al. Randomized, double-blind, crossover challenge study in 53 subjects reporting adverse reactions to melon (Cucumis melo). J Allergy Clin Immunol 2000; 106:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/2\">",
"      Rodriguez J, Crespo JF, Lopez-Rubio A, et al. Clinical cross-reactivity among foods of the Rosaceae family. J Allergy Clin Immunol 2000; 106:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/3\">",
"      Ortolani C, Ispano M, Pastorello E, et al. The oral allergy syndrome. Ann Allergy 1988; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/4\">",
"      Vieths S, Hoffmann A, Holzhauser T, et al. Factors influencing the quality of food extracts for in vitro and in vivo diagnosis. Allergy 1998; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/5\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/6\">",
"      Valenta R, Kraft D. Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. J Allergy Clin Immunol 1996; 97:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/7\">",
"      Kazemi-Shirazi L, Pauli G, Purohit A, et al. Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy. J Allergy Clin Immunol 2000; 105:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/8\">",
"      Fern&aacute;ndez-Rivas M, Bolhaar S, Gonz&aacute;lez-Mancebo E, et al. Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods. J Allergy Clin Immunol 2006; 118:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/9\">",
"      Smole U, Wagner S, Balazs N, et al. Bet v 1 and its homologous food allergen Api g 1 stimulate dendritic cells from birch pollen-allergic individuals to induce different Th-cell polarization. Allergy 2010; 65:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/10\">",
"      B&eacute;gin P, Des Roches A, Nguyen M, et al. Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen-induced oral allergy syndrome. J Allergy Clin Immunol 2011; 127:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/11\">",
"      Enrique E, Cister&oacute;-Bah&iacute;ma A, Bartolom&eacute; B, et al. Platanus acerifolia pollinosis and food allergy. Allergy 2002; 57:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/12\">",
"      Lauer I, Miguel-Moncin MS, Abel T, et al. Identification of a plane pollen lipid transfer protein (Pla a 3) and its immunological relation to the peach lipid-transfer protein, Pru p 3. Clin Exp Allergy 2007; 37:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/13\">",
"      Ebner C, Birkner T, Valenta R, et al. Common epitopes of birch pollen and apples--studies by western and northern blot. J Allergy Clin Immunol 1991; 88:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/14\">",
"      Ebner C, Hirschwehr R, Bauer L, et al. Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995; 95:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/15\">",
"      Breiteneder H, Radauer C. A classification of plant food allergens. J Allergy Clin Immunol 2004; 113:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/16\">",
"      Schimek EM, Zw&ouml;lfer B, Briza P, et al. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity. J Allergy Clin Immunol 2005; 116:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/17\">",
"      Bohle B, Zw&ouml;lfer B, Heratizadeh A, et al. Cooking birch pollen-related food: divergent consequences for IgE- and T cell-mediated reactivity in vitro and in vivo. J Allergy Clin Immunol 2006; 118:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/18\">",
"      Jahn-Schmid B, Radakovics A, L&uuml;ttkopf D, et al. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/19\">",
"      Bohle B. The impact of pollen-related food allergens on pollen allergy. Allergy 2007; 62:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/20\">",
"      Santos A, Van Ree R. Profilins: mimickers of allergy or relevant allergens? Int Arch Allergy Immunol 2011; 155:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/21\">",
"      Tordesillas L, Pacios LF, Palac&iacute;n A, et al. Characterization of IgE epitopes of Cuc m 2, the major melon allergen, and their role in cross-reactivity with pollen profilins. Clin Exp Allergy 2010; 40:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/22\">",
"      Pastorello EA, Farioli L, Pravettoni V, et al. The major allergen of peach (Prunus persica) is a lipid transfer protein. J Allergy Clin Immunol 1999; 103:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/23\">",
"      S&aacute;nchez-Monge R, Lombardero M, Garc&iacute;a-Sell&eacute;s FJ, et al. Lipid-transfer proteins are relevant allergens in fruit allergy. J Allergy Clin Immunol 1999; 103:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/24\">",
"      Schocker F, L&uuml;ttkopf D, Scheurer S, et al. Recombinant lipid transfer protein Cor a 8 from hazelnut: a new tool for in vitro diagnosis of potentially severe hazelnut allergy. J Allergy Clin Immunol 2004; 113:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/25\">",
"      Tejera ML, Villalba M, Batanero E, Rodr&iacute;guez R. Identification, isolation, and characterization of Ole e 7, a new allergen of olive tree pollen. J Allergy Clin Immunol 1999; 104:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/26\">",
"      Cuesta-Herranz J, L&aacute;zaro M, Mart&iacute;nez A, et al. Pollen allergy in peach-allergic patients: sensitization and cross-reactivity to taxonomically unrelated pollens. J Allergy Clin Immunol 1999; 104:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/27\">",
"      Krause S, Reese G, Randow S, et al. Lipid transfer protein (Ara h 9) as a new peanut allergen relevant for a Mediterranean allergic population. J Allergy Clin Immunol 2009; 124:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/28\">",
"      Fern&aacute;ndez-Rivas M, van Ree R, Cuevas M. Allergy to Rosaceae fruits without related pollinosis. J Allergy Clin Immunol 1997; 100:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/29\">",
"      Blein JP, Coutos-Th&eacute;venot P, Marion D, Ponchet M. From elicitins to lipid-transfer proteins: a new insight in cell signalling involved in plant defence mechanisms. Trends Plant Sci 2002; 7:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/30\">",
"      D&iacute;az-Perales A, Lombardero M, S&aacute;nchez-Monge R, et al. Lipid-transfer proteins as potential plant panallergens: cross-reactivity among proteins of Artemisia pollen, Castanea nut and Rosaceae fruits, with different IgE-binding capacities. Clin Exp Allergy 2000; 30:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/31\">",
"      Asero R, Mistrello G, Roncarolo D, et al. Immunological cross-reactivity between lipid transfer proteins from botanically unrelated plant-derived foods: a clinical study. Allergy 2002; 57:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/32\">",
"      Asero R, Mistrello G, Roncarolo D, et al. A case of allergy to beer showing cross-reactivity between lipid transfer proteins. Ann Allergy Asthma Immunol 2001; 87:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/33\">",
"      Breiteneder H, Mills C. Nonspecific lipid-transfer proteins in plant foods and pollens: an important allergen class. Curr Opin Allergy Clin Immunol 2005; 5:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/34\">",
"      Sancho AI, Rigby NM, Zuidmeer L, et al. The effect of thermal processing on the IgE reactivity of the non-specific lipid transfer protein from apple, Mal d 3. Allergy 2005; 60:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/35\">",
"      Asero R, Mistrello G, Roncarolo D, et al. Lipid transfer protein: a pan-allergen in plant-derived foods that is highly resistant to pepsin digestion. Int Arch Allergy Immunol 2001; 124:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/36\">",
"      Fern&aacute;ndez-Rivas M, Gonz&aacute;lez-Mancebo E, Rodr&iacute;guez-P&eacute;rez R, et al. Clinically relevant peach allergy is related to peach lipid transfer protein, Pru p 3, in the Spanish population. J Allergy Clin Immunol 2003; 112:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/37\">",
"      Ballmer-Weber BK. Lipid transfer protein as a potential panallergen? Allergy 2002; 57:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/38\">",
"      Scheurer S, Pastorello EA, Wangorsch A, et al. Recombinant allergens Pru av 1 and Pru av 4 and a newly identified lipid transfer protein in the in vitro diagnosis of cherry allergy. J Allergy Clin Immunol 2001; 107:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/39\">",
"      Schulten V, Radakovics A, Hartz C, et al. Characterization of the allergic T-cell response to Pru p 3, the nonspecific lipid transfer protein in peach. J Allergy Clin Immunol 2009; 124:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/40\">",
"      Klinglmayr E, Hauser M, Zimmermann F, et al. Identification of B-cell epitopes of Bet v 1 involved in cross-reactivity with food allergens. Allergy 2009; 64:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/41\">",
"      Hoffmann-Sommergruber K, Vanek-Krebitz M, Ferris R, et al. Isolation and cloning of Bet v 1-homologous food allergens from celeriac (Api g1) and apple (Mal d1). Adv Exp Med Biol 1996; 409:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/42\">",
"      Bolhaar ST, van de Weg WE, van Ree R, et al. In vivo assessment with prick-to-prick testing and double-blind, placebo-controlled food challenge of allergenicity of apple cultivars. J Allergy Clin Immunol 2005; 116:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/43\">",
"      Hsieh LS, Moos M Jr, Lin Y. Characterization of apple 18 and 31 kd allergens by microsequencing and evaluation of their content during storage and ripening. J Allergy Clin Immunol 1995; 96:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/44\">",
"      Sancho AI, Foxall R, Browne T, et al. Effect of postharvest storage on the expression of the apple allergen Mal d 1. J Agric Food Chem 2006; 54:5917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/45\">",
"      Hirschwehr R, Valenta R, Ebner C, et al. Identification of common allergenic structures in hazel pollen and hazelnuts: a possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. J Allergy Clin Immunol 1992; 90:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/46\">",
"      Schocker F, L&uuml;ttkopf D, M&uuml;ller U, et al. IgE binding to unique hazelnut allergens: identification of non pollen-related and heat-stable hazelnut allergens eliciting severe allergic reactions. Eur J Nutr 2000; 39:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/47\">",
"      Flinterman AE, Akkerdaas JH, den Hartog Jager CF, et al. Lipid transfer protein-linked hazelnut allergy in children from a non-Mediterranean birch-endemic area. J Allergy Clin Immunol 2008; 121:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/48\">",
"      Hansen KS, Ballmer-Weber BK, Sastre J, et al. Component-resolved in vitro diagnosis of hazelnut allergy in Europe. J Allergy Clin Immunol 2009; 123:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/49\">",
"      Mittag D, Akkerdaas J, Ballmer-Weber BK, et al. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. J Allergy Clin Immunol 2004; 114:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/50\">",
"      van Ree R, Fern&aacute;ndez-Rivas M, Cuevas M, et al. Pollen-related allergy to peach and apple: an important role for profilin. J Allergy Clin Immunol 1995; 95:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/51\">",
"      Cuesta-Herranz J, L&aacute;zaro M, de las Heras M, et al. Peach allergy pattern: experience in 70 patients. Allergy 1998; 53:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/52\">",
"      Cuesta-Herranz J, L&aacute;zaro M, Figueredo E, et al. Allergy to plant-derived fresh foods in a birch- and ragweed-free area. Clin Exp Allergy 2000; 30:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/53\">",
"      Asero R, Mistrello G, Amato S, et al. Peach fuzz contains large amounts of lipid transfer protein: is this the cause of the high prevalence of sensitization to LTP in Mediterranean countries? Eur Ann Allergy Clin Immunol 2006; 38:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/54\">",
"      Pastorello EA, Ortolani C, Farioli L, et al. Allergenic cross-reactivity among peach, apricot, plum, and cherry in patients with oral allergy syndrome: an in vivo and in vitro study. J Allergy Clin Immunol 1994; 94:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/55\">",
"      Hoffmann-Sommergruber K, O'Riordain G, Ahorn H, et al. Molecular characterization of Dau c 1, the Bet v 1 homologous protein from carrot and its cross-reactivity with Bet v 1 and Api g 1. Clin Exp Allergy 1999; 29:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/56\">",
"      Ballmer-Weber BK, W&uuml;thrich B, Wangorsch A, et al. Carrot allergy: double-blinded, placebo-controlled food challenge and identification of allergens. J Allergy Clin Immunol 2001; 108:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/57\">",
"      G&oacute;mez M, Curiel G, Mendez J, et al. Hypersensitivity to carrot associated with specific IgE to grass and tree pollens. Allergy 1996; 51:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/58\">",
"      Kleine-Tebbe J, Vogel L, Crowell DN, et al. Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22. J Allergy Clin Immunol 2002; 110:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/59\">",
"      Mittag D, Vieths S, Vogel L, et al. Soybean allergy in patients allergic to birch pollen: clinical investigation and molecular characterization of allergens. J Allergy Clin Immunol 2004; 113:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/60\">",
"      Gall H, Kalveram KJ, Forck G, Sterry W. Kiwi fruit allergy: a new birch pollen-associated food allergy. J Allergy Clin Immunol 1994; 94:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/61\">",
"      Alem&aacute;n A, Sastre J, Quirce S, et al. Allergy to kiwi: a double-blind, placebo-controlled food challenge study in patients from a birch-free area. J Allergy Clin Immunol 2004; 113:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/62\">",
"      Pastorello EA, Pravettoni V, Ispano M, et al. Identification of the allergenic components of kiwi fruit and evaluation of their cross-reactivity with timothy and birch pollens. J Allergy Clin Immunol 1996; 98:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/63\">",
"      Bublin M, Pfister M, Radauer C, et al. Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens. J Allergy Clin Immunol 2010; 125:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/64\">",
"      Anderson LB Jr, Dreyfuss EM, Logan J, et al. Melon and banana sensitivity coincident with ragweed pollinosis. J Allergy 1970; 45:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/65\">",
"      Liccardi G, Mistrello G, Noschese P, et al. Oral allergy syndrome (OAS) in pollinosis patients after eating pistachio nuts: two cases with two different patterns of onset. Allergy 1996; 51:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/66\">",
"      Reindl J, Anliker MD, Karamloo F, et al. Allergy caused by ingestion of zucchini (Cucurbita pepo): characterization of allergens and cross-reactivity to pollen and other foods. J Allergy Clin Immunol 2000; 106:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/67\">",
"      W&uuml;thrich B, St&auml;ger J, Johansson SG. Celery allergy associated with birch and mugwort pollinosis. Allergy 1990; 45:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/68\">",
"      Egger M, Mutschlechner S, Wopfner N, et al. Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view. Allergy 2006; 61:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/69\">",
"      Yagami A, Nakazawa Y, Suzuki K, Matsunaga K. Curry spice allergy associated with pollen-food allergy syndrome and latex fruit-syndrome. J Dermatol 2009; 36:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/70\">",
"      Bublin M, Radauer C, Wilson IB, et al. Cross-reactive N-glycans of Api g 5, a high molecular weight glycoprotein allergen from celery, are required for immunoglobulin E binding and activation of effector cells from allergic patients. FASEB J 2003; 17:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/71\">",
"      Ballmer-Weber BK, Hoffmann A, W&uuml;thrich B, et al. Influence of food processing on the allergenicity of celery: DBPCFC with celery spice and cooked celery in patients with celery allergy. Allergy 2002; 57:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/72\">",
"      Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/73\">",
"      Blanco C, Carrillo T, Castillo R, et al. Latex allergy: clinical features and cross-reactivity with fruits. Ann Allergy 1994; 73:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/74\">",
"      Garc&iacute;a Ortiz JC, Moyano JC, Alvarez M, Bellido J. Latex allergy in fruit-allergic patients. Allergy 1998; 53:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/75\">",
"      Blanco C, Carrillo T, Castillo R, et al. Avocado hypersensitivity. Allergy 1994; 49:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/76\">",
"      Brehler R, Theissen U, Mohr C, Luger T. \"Latex-fruit syndrome\": frequency of cross-reacting IgE antibodies. Allergy 1997; 52:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5785/abstract/77\">",
"      Nel A, Gujuluva C. Latex antigens: identification and use in clinical and experimental studies, including crossreactivity with food and pollen allergens. Ann Allergy Asthma Immunol 1998; 81:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2403 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5785=[""].join("\n");
var outline_f5_41_5785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5003846\">",
"      Sensitization to pollen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALLERGENS IN PFAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Birch pollen-related allergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bet v 1-cross-reactive antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Profilins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ALLERGENS IN ISOLATED FRUIT/VEGETABLE ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonspecific lipid transfer proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALLERGENS IN SPECIFIC FOODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Apple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hazelnut",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Peanut",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Celery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Peach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Carrot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Soybean",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Kiwi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Melons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SYNDROMES ASSOCIATED WITH SYSTEMIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Celery-mugwort-spice syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Mugwort-mustard syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Latex-fruit syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2403|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/1/16409\" title=\"figure 1\">",
"      Food-pollen relationships",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/46/9952\" title=\"figure 2\">",
"      OAS food food cross rxn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/50/801\" title=\"figure 3\">",
"      Latex food cross rxn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2403|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/47/13048\" title=\"table 1\">",
"      Risk of anaphylaxis with plant food allergens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=related_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_41_5786="Treatment of fibromyalgia in adults not responsive to initial therapies";
var content_f5_41_5786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of fibromyalgia in adults not responsive to initial therapies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5786/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5786/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5786/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/41/5786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/41/5786/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/41/5786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22299051\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is a chronic pain disorder that is often difficult to treat. Effective interventions include a number of nonpharmacologic and pharmacologic therapies that are often provided in combination. Patients with fibromyalgia generally respond best to a multidisciplinary, individualized treatment program that incorporates physician as well as non-physician providers, including physical medicine, rehabilitation, and mental health specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of fibromyalgia in adults who are not responsive to initial therapies will be reviewed here. The initial treatment and prognosis of fibromyalgia in adults; the pathogenesis, clinical manifestations, diagnosis, and differential diagnosis of fibromyalgia; and fibromyalgia in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=see_link\">",
"     \"Pathogenesis of fibromyalgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35608?source=see_link\">",
"     \"Differential diagnosis of fibromyalgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281622868\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of fibromyalgia is directed at reducing the major symptoms of this disorder, including chronic widespread pain, fatigue, insomnia, and cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. A variety of modalities are employed, using a stepwise approach (",
"    <a class=\"graphic graphic_table graphicRef60515 \" href=\"UTD.htm?23/54/24427\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351008095\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our initial approach to the treatment of patients with fibromyalgia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, the initial steps in therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient education regarding the disease, the treatment approaches, good sleep hygiene, and the importance of treating comorbidities that may contribute to symptoms, including mood or sleep disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H352170621#H352170621\">",
"       \"Initial treatment of fibromyalgia in adults\", section on 'Patient education'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An exercise program, including aerobic conditioning, stretching, and strengthening (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H352172117#H352172117\">",
"       \"Initial treatment of fibromyalgia in adults\", section on 'Exercise'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug monotherapy for treatment of symptoms not relieved by nonpharmacologic measures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H5#H5\">",
"       \"Initial treatment of fibromyalgia in adults\", section on 'Medications'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351008102\">",
"    <span class=\"h2\">",
"     Patients not responsive to initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients experience continued symptoms despite initial nonpharmacologic measures and treatment with a single drug at the maximum tolerated dose; we advise the continued use of several different treatment modalities in such patients, including both nonpharmacologic and pharmacologic treatment measures. The specific intervention depends upon symptoms, patient preferences regarding the types of therapies, available resources, and expertise. These interventions are not mutually exclusive and may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combinations of drugs (see",
"      <a class=\"local\" href=\"#H22299532\">",
"       'Combination drug therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Referral for a supervised physical medicine and rehabilitation evaluation and treatment program (see",
"      <a class=\"local\" href=\"#H351009661\">",
"       'Exercise and physical therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Referral for psychological interventions for pain management, including cognitive behavioral therapy and other interventions (see",
"      <a class=\"local\" href=\"#H22299539\">",
"       'Psychological therapies'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Consultation with one or more specialists, depending upon the specific expertise needed, such as a rheumatologist, physiatrist, psychiatrist, psychologist, or pain management specialist (see",
"      <a class=\"local\" href=\"#H351008147\">",
"       'Consultation and referral'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Assessment and care in a specialized multidisciplinary program, particularly for patients with disease refractory to other interventions or on chronic opioids (see",
"      <a class=\"local\" href=\"#H281624293\">",
"       'Multidisciplinary treatment programs'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Other treatments, including medications for which there is more limited evidence, and complementary and alternative measures, including &ldquo;mind-body&rdquo; therapies such as tai chi and yoga (see",
"      <a class=\"local\" href=\"#H22300507\">",
"       'Analgesic and antiinflammatory drugs'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22300536\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22300584\">",
"       'Complementary and alternative therapies'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonpharmacologic interventions are important in the initial management of fibromyalgia; these and other nonpharmacologic interventions are also beneficial to patients with disease that does not respond to initial therapies. Some patients respond sufficiently well without drug therapy to avoid the need for medications; this is more common among those presenting in the primary care setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H7185818#H7185818\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Overview of treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22299532\">",
"    <span class=\"h1\">",
"     COMBINATION DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the use of combination drug therapy in most patients unresponsive to monotherapy, based upon the symptoms that most affect the patient. These recommendations are based largely upon clinical experience, as there is relatively little data regarding the relative benefits or adverse effects of drug combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/6\">",
"     6",
"    </a>",
"    ]. The evidence for efficacy of each of the individual drugs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We combine drugs of different classes, to take advantage of multiple mechanisms of action for reducing pain and to target different symptoms. A variety of combinations may be effective, and selection of specific agents depends upon patient tolerance, drug availability, cost to the patient, and comorbidities that may be present, such as psychiatric illness. Examples of combinations we have used are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low dose of a serotonin and norepinephrine reuptake inhibitor (SNRI) (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ) in the morning with a low dose of an anticonvulsant (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      ) in the evening. This combination has not been evaluated in randomized trials but has been effective in our experience, and it is proposed as a combination with high therapeutic potential based upon a systematic review and meta-analysis of single-agent randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H1979157#H1979157\">",
"       \"Initial treatment of fibromyalgia in adults\", section on 'Duloxetine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H352171902#H352171902\">",
"       \"Initial treatment of fibromyalgia in adults\", section on 'Pregabalin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A low dose of a selective serotonin reuptake inhibitor (SSRI) (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ) or an SNRI in the morning with a low dose of tricyclic antidepressant (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ) in the evening. As an example, the treatment for six weeks with a combination of 20 mg of fluoxetine in the morning and 25 mg of amitriptyline at bedtime was more effective than either medication used alone in a single randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/8\">",
"       8",
"      </a>",
"      ]. Patients reported significantly greater improvement in pain with the combination of agents compared with fluoxetine or amitriptyline alone or with placebo (visual analogue pain scale score, with maximum of 100, of 43 versus 58 and of 64 versus 82). (See",
"      <a class=\"local\" href=\"#H22300536\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H8#H8\">",
"       \"Initial treatment of fibromyalgia in adults\", section on 'Tricyclic antidepressants as initial drug therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians with insufficient experience in the use of these medications or drug combinations may wish to consult with an expert in the pharmacologic treatment of fibromyalgia, such as a rheumatologist. In patients who also have a comorbid psychiatric illness, we advise consultation with a psychiatrist for assistance in medication management and coordination of care. (See",
"    <a class=\"local\" href=\"#H351008147\">",
"     'Consultation and referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients without an adequate response to these medications or with a temporary need for additional treatment during an exacerbation of pain symptoms, other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , and nonsteroidal antiinflammatory drugs (NSAIDs) are adjunctive or alternative therapies that may be helpful. Other antidepressants may also be used in some patients as alternative agents; however, there is less evidence for their benefit than the tricyclics, SNRIs, SSRIs, or anticonvulsants cited above. (See",
"    <a class=\"local\" href=\"#H22300507\">",
"     'Analgesic and antiinflammatory drugs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22300536\">",
"     'Selective serotonin reuptake inhibitors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22300521\">",
"     'Antiinflammatory medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other medications that have been used in patients with fibromyalgia include opioid analgesics other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , muscle relaxants, and stimulants, but there is insufficient evidence for their efficacy or safety in the treatment of fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22300452\">",
"     'Other therapies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22300514\">",
"     'Analgesics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351009661\">",
"    <span class=\"h1\">",
"     EXERCISE AND PHYSICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have had difficulty achieving a sufficient level of low impact aerobic exercise, we encourage participation in a supervised physical therapy program. Evidence supporting the efficacy of exercise training is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H352172356#H352172356\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Efficacy of exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We refer patients with continued difficulties with exercise or physical functioning to a physiatrist for further evaluation and for assistance in management. (See",
"    <a class=\"local\" href=\"#H351008147\">",
"     'Consultation and referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional forms of exercise that have shown some benefit in fibromyalgia but which are not primarily directed at developing aerobic fitness include &ldquo;mind-body&rdquo; interventions such as tai chi and yoga. (See",
"    <a class=\"local\" href=\"#H22300591\">",
"     'Tai chi'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22300598\">",
"     'Yoga'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22299539\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients whose symptoms do not respond adequately to initial therapies, we suggest referral through a multidisciplinary treatment program or to a behavioral specialist for psychological interventions, such as cognitive behavioral therapy (CBT); the specific interventions should be individualized based upon patient preference and available resources [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Psychological interventions should be integrated with multidisciplinary treatment that also includes pharmacologic therapy, education, and exercise. (See",
"    <a class=\"local\" href=\"#H351008147\">",
"     'Consultation and referral'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H281624293\">",
"     'Multidisciplinary treatment programs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A role for psychological therapies, particularly CBT, in the treatment of fibromyalgia is well-supported by evidence from meta-analyses, individual trials, and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2,3,9,11-17\">",
"     2,3,9,11-17",
"    </a>",
"    ]. In addition to CBT, measures that are helpful include mindfulness-based treatments, relaxation, biofeedback, behavioral treatments, and educational interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2,3,11,13-17\">",
"     2,3,11,13-17",
"    </a>",
"    ]. Additionally, education, focusing on self-management, combined with exercise enhances the benefits of exercise in fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H352170655#H352170655\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Effectiveness of patient education'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2010 meta-analysis of 23 studies of 30 psychological treatment conditions, involving 1396 patients, found significant short- and long-term benefit for a number of measures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/11\">",
"     11",
"    </a>",
"    ]. The authors of the meta-analysis concluded that patients with fibromyalgia should be treated with a combination of methods that include psychological interventions as a major component, such as high-dose CBT with relaxation or biofeedback. The major findings of this analysis included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analysis of any psychological intervention showed statistically significant but small effects on short-term pain reduction and a small to medium effect for long-tem pain reduction (average follow-up 7.4 months). The level of benefit from psychological treatments was similar to that from treatment with drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. As an example of the level of benefit, in one small trial, there were statistically nonsignificant 18 percent reductions in self-reported pain scores compared with baseline with either CBT or with a physical exercise program [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CBT resulted in significantly greater benefit in short-term fibromyalgia pain reduction than other psychological treatments, and CBT, relaxation, and biofeedback were significantly more effective than other psychological treatments in reducing sleep problems. All psychological treatments were comparably effective in decreasing depression, and higher treatment dose was associated with greater reductions in depression and in pain intensity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with significant cognitive dysfunction despite other therapies, referral to an expert in cognitive impairment, such as a neurologist, may be of benefit to determine whether other causes for cognitive dysfunction are present and if further diagnostic and therapeutic interventions are required. Some patients may also benefit from consultation with a clinical psychologist for neuropsychological (psychometric) testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link&amp;anchor=H18#H18\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Neuropsychological testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112654338\">",
"    <span class=\"h1\">",
"     FACTORS LIMITING TREATMENT EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors may limit the degree of benefit achieved with prescribed medications or other interventions, including nonadherence to treatment interventions or comorbidities that cause peripheral pain and that require additional interventions to those used for treatment of the fibromyalgia. (See",
"    <a class=\"local\" href=\"#H112654434\">",
"     'Nonadherence to treatment recommendations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H112654470\">",
"     'Treating peripheral pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112654434\">",
"    <span class=\"h2\">",
"     Nonadherence to treatment recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lack of adherence to the prescribed treatment program is common in fibromyalgia and should also be evaluated as a potential cause of persistent symptoms. Noncompliance, whether due to forgetfulness, due to carelessness, or as an exercise of patient autonomy, may contribute to a lack of effectiveness of medications prescribed for patients with fibromyalgia. Adherence to advice by patients with fibromyalgia cared for by 10 rheumatologists was assessed in a study of 127 women with fibromyalgia recruited from both tertiary care hospitals and the community [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/22\">",
"     22",
"    </a>",
"    ]. Overall, 47 percent of the women reported noncompliance with medications. The degree of discordance between a clinician&rsquo;s and patient&rsquo;s assessments of communication during, as well as patient satisfaction at the conclusion of, a clinician-patient encounter was a significant determinant of overall compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112654470\">",
"    <span class=\"h2\">",
"     Treating peripheral pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;We treat other sources of pain, such as arthritis or regional pain syndromes, which may also contribute to the patient&rsquo;s symptoms. Patients with nociceptive pain may require other agents, such as analgesics or antiinflammatory or immunosuppressive drugs, depending upon the condition (eg, osteoarthritis or rheumatoid arthritis) causing such pain.",
"   </p>",
"   <p>",
"    Treating peripheral pain generators, such as myofascial trigger points, may also improve symptoms of fibromyalgia. The local and referred pain pattern induced from active myofascial trigger points bilaterally in the upper trapezius muscle was similar to the ongoing pain pattern in the neck and shoulder region in fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/23\">",
"     23",
"    </a>",
"    ]. Furthermore, treating active trigger points improved localized pain, as well as fibromyalgia symptoms and analgesic consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/24\">",
"     24",
"    </a>",
"    ]. The proposed mechanism by which localized muscle and joint pain affects significantly on fibromyalgia is through increased central sensitization by peripheral input. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of soft tissue rheumatic disorders\", section on 'Regional myofascial pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351008147\">",
"    <span class=\"h1\">",
"     CONSULTATION AND REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have not responded adequately to initial therapies and combination drug therapy with major agents (eg, tricyclics, dual-uptake inhibitors [SNRIs], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ), we obtain the following specialty consultations for further evaluation and assistance in management, depending upon the expertise of the treating clinician and upon the patient&rsquo;s symptoms and comorbidities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We advise consultation with a rheumatologist for the following indications:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients for whom assistance is needed in prescribing combination drug therapies or in coordinating multidisciplinary management",
"     </li>",
"     <li>",
"      For confirmation of the diagnosis and for re-evaluation of the treatment program in patients unresponsive to initial therapies and combination drug therapy",
"     </li>",
"     <li>",
"      For evaluation and assistance in management of comorbid musculoskeletal conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We advise consultation with a physiatrist for the following indications:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients who have had difficulty achieving a sufficient level of low-impact aerobic exercise or who have had continued difficulties with exercise or physical functioning, despite a trial of a supervised physical therapy program (see",
"      <a class=\"local\" href=\"#H351009661\">",
"       'Exercise and physical therapy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      For treatment of regional myofascial pain using trigger point injections and other techniques, which may be of benefit for both the local and the more generalized pain symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We advise consultation with a psychiatrist for the following indications:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients who continue to experience symptoms of a mood disorder despite treatment or for whom assistance in treatment is needed",
"     </li>",
"     <li>",
"      In patients in whom a mood disorder or other psychiatric condition is present and for whom assistance is needed in management of multiple agents with potential psychopharmacologic effects that are being employed for treatment of fibromyalgia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We advise referral for formal testing for a sleep disorder and assistance in management in patients with symptoms of a sleep disorder, such as obstructive sleep apnea or restless legs syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281624293\">",
"    <span class=\"h2\">",
"     Multidisciplinary treatment programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should generally be multidisciplinary and should be individualized with attention to the patient&rsquo;s particular symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Such treatment can be facilitated by multidisciplinary treatment programs. These may be developed in physical medicine and rehabilitation centers by physiatrists or in chronic pain units [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/25\">",
"     25",
"    </a>",
"    ]. Rheumatologists or others may also provide this care, particularly if they work closely with physiatrists, physical therapists, and mental health professionals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/26\">",
"     26",
"    </a>",
"    ]. The advantage of such a program is to provide a structured, multimodality treatment program under one roof and in a relatively brief time frame. This type of program may be especially helpful in patients who are resistant to drug therapy and in those patients with the most complicated psychosocial issues, including disability proceedings.",
"   </p>",
"   <p>",
"    Significant benefits of multicomponent treatment were documented in a meta-analysis involving 1119 patients with fibromyalgia in nine randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/27\">",
"     27",
"    </a>",
"    ]. For inclusion in the meta-analysis, multicomponent treatment needed to include at least one educational or other psychological therapy and at least one exercise therapy; the controls for comparison with the multicomponent treatment also varied but were required to be a control receiving no treatment, receiving treatment as usual, or receiving another well-defined treatment with a lower intensity than the multicomponent intervention. There was evidence of significant reductions in pain, fatigue, depressive symptoms, and limitations to health-related quality of life (HRQOL), and patients had improved self-efficacy for pain (belief in one&rsquo;s ability to accomplish a task or cope with pain) at the end of the treatment program but not after longer term follow-up (median of seven months). Physical fitness was improved both after treatment and after follow-up.",
"   </p>",
"   <p>",
"    Multidisciplinary rehabilitation programs may also aid in reducing use of opioids and other analgesics in patients taking these medications. As an example, an uncontrolled study admitted 159 fibromyalgia patients to a multidisciplinary pain rehabilitation program based upon cognitive behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/28\">",
"     28",
"    </a>",
"    ]. Physical and emotional function improved, and the use of analgesics, including opioids, was reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281624300\">",
"    <span class=\"h2\">",
"     Role of pain clinics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor the use of pain clinics that are participants in or centers for a multidisciplinary approach to fibromyalgia therapy. Such centers are typically accessed through consultation with other providers with expertise in the care of patients with fibromyalgia. We generally avoid referral to pain clinics that lack such interest and expertise, as many of the approaches typically employed in latter types of centers include strategies that have not proven effective in the chronic management of fibromyalgia, such as interventional procedures and chronic opioid use. We usually limit referral to pain clinics that are not involved in multidisciplinary fibromyalgia treatment programs to patients with inadequate control of symptoms in whom other proven nonpharmacologic and medical interventions have been optimized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300452\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several approaches may be tried in patients who do not respond to the specific therapies outlined above, including both nonpharmacologic and pharmacologic therapies. Most of these additional approaches are supported by more limited evidence. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Analgesics and antiinflammatory drugs (see",
"      <a class=\"local\" href=\"#H22300507\">",
"       'Analgesic and antiinflammatory drugs'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22300514\">",
"       'Analgesics'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22300521\">",
"       'Antiinflammatory medications'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Alternative antidepressants (see",
"      <a class=\"local\" href=\"#H22300536\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Complementary and alternative therapies (see",
"      <a class=\"local\" href=\"#H22300584\">",
"       'Complementary and alternative therapies'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300507\">",
"    <span class=\"h2\">",
"     Analgesic and antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesic and antiinflammatory drugs other than antidepressants and other established central nervous system (CNS) active medications have been used in the treatment of fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300514\">",
"    <span class=\"h3\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use analgesics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , alone or in combination in patients who require additional pain relief on a temporary basis for a disease exacerbation or in whom other therapies have been inadequate for controlling pain. There are limited studies that show benefit from these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. They are generally used in combination with CNS active medications when the latter are not effective alone. Tramadol is a novel analgesic that has activity at mu opioid receptors but that also inhibits the reuptake of serotonin and norepinephrine, which may contribute to its analgesic effect in chronic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link&amp;anchor=H9191451#H9191451\">",
"     \"Overview of the treatment of chronic pain\", section on 'Tramadol and tapentadol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest clinical efficacy of the fixed combination of these two agents (up to 650 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and 75 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    four times daily) in relieving pain was illustrated in a study that randomly assigned 315 predominantly white female patients to active combination therapy or to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/30\">",
"     30",
"    </a>",
"    ]. Discontinuation rates and secondary measures such as pain, pain relief, and self-reported health status were assessed over a three-month period. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater proportion of the patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      had a 50 percent or greater reduction in pain (35 versus 18 percent with placebo).",
"     </li>",
"     <li>",
"      Those on the active combination had significantly greater overall decrease in pain (19 versus 7 mm on a 100 mm scale).",
"     </li>",
"     <li>",
"      Discontinuation rates were lower with active treatment (48 versus 62 percent). Nausea was more than twice as common among those on the active medication compared with those on placebo (9 versus 4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these findings are encouraging, the patients had received little treatment before enrollment, and prior uses of tricyclic antidepressants, of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    , and of analgesics (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ) were criteria for exclusion. It is uncertain how effective the combination of acetaminophen and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    would be for patients who had tried and failed other treatments or how the combination would perform if added to ongoing treatment with one or more of the CNS active medications.",
"   </p>",
"   <p>",
"    There is some concern regarding the long-term potential for abuse of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , a weak opioid, although the risks and adverse effects may theoretically be less than those of more potent narcotic analgesics that have also been tried in fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/31\">",
"     31",
"    </a>",
"    ]. Prolonged use of such agents in fibromyalgia is controversial, and we prefer that a pain management specialist be involved in the care of those patients who are receiving strong opioids on a long-term basis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of chronic pain\", section on 'Opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a lack evidence that opioids other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    are effective in the treatment of fibromyalgia, and possible adverse effects may outweigh the potential for limited or short-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300521\">",
"    <span class=\"h3\">",
"     Antiinflammatory medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not use nonsteroidal antiinflammatory drugs (NSAIDs) as the primary drug for pain in patients with fibromyalgia, and we do not use glucocorticoids in this condition. Several small randomized trials have failed to show that that antiinflammatory medications are effective forms of treatment; therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    were each found to be no better than placebo in these trials, which generally also permitted the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2,33-35\">",
"     2,33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there is no evidence that tissue inflammation is present in patients with fibromyalgia, and glucocorticoids also have the potential for serious adverse effects when used chronically [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, any benefit experienced with NSAIDs is likely due to the analgesic effects of these agents alone.",
"   </p>",
"   <p>",
"    However, NSAIDs may have a synergistic beneficial effect on pain when combined with central nervous system (CNS) active medications such as antidepressants or anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/33\">",
"     33",
"    </a>",
"    ]. NSAIDs may also provide additional benefit in patients with nociceptive pain from arthritis or other conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300536\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other CNS active medications that have some efficacy in fibromyalgia (in addition to tricyclics, SNRIs, and anticonvulsants) include the selective serotonin reuptake inhibitors (SSRIs). However, trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    have shown mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/8,36,37\">",
"     8,36,37",
"    </a>",
"    ], and small trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    have also been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Other drugs that have been studied include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/40\">",
"     40",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/41\">",
"     41",
"    </a>",
"    ]. In some patients, however, a trial of these agents may be warranted, particularly if cost to the patient precludes use of a more effective alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available evidence regarding the efficacy of SSRIs for fibromyalgia includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      &mdash; One study found that a fixed dose of fluoxetine (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was not superior to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/37\">",
"       37",
"      </a>",
"      ], while another that allowed dose escalation, from 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to a maximum of 80",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      found fluoxetine to be significantly more effective than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/36\">",
"       36",
"      </a>",
"      ]. In this study, the effect on pain was independent of change in mood.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      &mdash; In a trial that randomly assigned 116 patients either to an escalating dose of a continuous release formulation of paroxetine (12.5 to 62.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or to placebo, composite scores on the fibromyalgia impact questionnaire (FIQ) were followed from baseline to 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/40\">",
"       40",
"      </a>",
"      ]. Significantly more of those assigned to paroxetine than to placebo achieved a &ge;25 percent improvement in FIQ score (57 versus 33 percent). Among those who completed the assigned treatment, the response rates were higher in those receiving paroxetine than placebo (66 versus 33 percent, respectively).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"      &mdash; Fluvoxamine was compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      in a study that randomly assigned 68 patients to one of the two active treatments for four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/41\">",
"       41",
"      </a>",
"      ]. Withdrawals were more common in the amitriptyline group than in the fluvoxamine group (40 versus 16 percent). Pain relief was not significantly different in the two groups.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"      &mdash; Inconsistent results have been noted in small studies using citalopram to treat patients with fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300584\">",
"    <span class=\"h2\">",
"     Complementary and alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some evidence has suggested that tai chi, yoga, or acupuncture may have benefit in fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. These interventions may be of particular interest to some patients, especially those who wish to avoid the use of additional medications or the use of any medications at all.",
"   </p>",
"   <p>",
"    A systematic literature review has found insufficient evidence of efficacy for fibromyalgia of a number of oral or topically applied complementary, alternative, and other therapies, including anthocyanidin, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , dietary soy, S-adenosyl methionine, or homeopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300591\">",
"    <span class=\"h3\">",
"     Tai chi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tai chi, which combines mind-body practice with gentle, flowing movement exercises, has shown some benefit for fibromyalgia symptoms, although it has not been extensively studied for this condition. A randomized trial involving 66 patients compared tai chi (one-hour sessions twice weekly) with a control intervention of wellness education and stretching, with significant improvement in the Fibromyalgia Impact Questionnaire score in the group receiving tai chi after 12 weeks of the intervention (baseline versus 12-week scores of 63 &plusmn; 16 and 35 &plusmn; 19 versus 68 &plusmn; 11 and 59 &plusmn; 18, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/42\">",
"     42",
"    </a>",
"    ]. Improvements were maintained at 24 weeks, and no adverse events were observed.",
"   </p>",
"   <p>",
"    Additional larger and longer-term studies will be needed to replicate these findings and to more clearly establish whether there is a role for tai chi in the management of fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300598\">",
"    <span class=\"h3\">",
"     Yoga",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized controlled trial evaluated a specific form of yoga, called Yoga of Awareness, in 53 fibromyalgia patients who were compared with wait-listed standard care. Those receiving the yoga program demonstrated greater improvements in pain, fatigue, and mood and in pain catastrophizing, acceptance, and other coping strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300605\">",
"    <span class=\"h3\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies, but not others, have found traditional Chinese acupuncture to be effective compared with various sham procedures for relieving pain in patients with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Acupuncture has also been shown to reduce symptoms of chronic pain in a variety of other conditions but generally provides a similar level of benefit to sham acupuncture controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"     \"Acupuncture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For example, in one report, all treatment groups experienced a substantial decrease in pain from baseline; however, the mean difference in pain relief between the traditional acupuncture group and all the sham groups was insignificant (0.5 cm on a 10 cm scale, 95% CI -0.3 to 1.2 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2010 systematic review and meta-analysis of acupuncture therapy, involving 385 patients with FM in seven randomized trials, showed evidence for pain reduction after treatment (standardized mean difference [SMD] -0.25, 95% CI -0.49 to -0.02) but not at the latest follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/47\">",
"     47",
"    </a>",
"    ]. There was no evidence post-treatment of reduced fatigue or sleep disturbance or of improved physical function. Subgroup analyses found some benefit in studies using electrostimulation and individualized acupuncture. However, significant pain reduction was found only in studies with a risk of bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085033\">",
"    <span class=\"h2\">",
"     Injection therapies and other physical measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been few studies of trigger point or tender point injections, EMG-biofeedback, chiropractic, or massage in the treatment of fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Most of these reports are from small case series or lack quality control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22300619\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of investigational approaches have been studied, including medications and other strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/48-61\">",
"     48-61",
"    </a>",
"    ]. Of note are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"       Pramipexole",
"      </a>",
"      &mdash; Benefit from pramipexole, a dopamine agonist, was shown in a study that randomly assigned patients either to pramipexole (0.5 mg to a maximum of 4.5 mg every evening) or to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/48\">",
"       48",
"      </a>",
"      ]. Significantly greater improvement in the mean pain score was seen with pramipexole after 14 weeks. Higher doses were used than many patients can tolerate, however, and patients were left on their other medications, including opioids, in many instances. Thus, further study is needed to evaluate its efficacy and safety. We suggest limiting the use of pramipexole in fibromyalgia to patients who are refractory to the multiple better-established medications and other interventions described above.",
"     </li>",
"     <li>",
"      Esreboxetine &mdash; An investigational, selective norepinephrine reuptake inhibitor, esreboxetine, showed benefit compared with placebo in a multicenter, randomized, eight-week trial involving 267 patients with fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/62\">",
"       62",
"      </a>",
"      ]. Significantly greater improvement was seen in pain, in fibromyalgia symptoms, in functional impairment, and in overall status compared with patients receiving placebo.",
"     </li>",
"     <li>",
"      Other medications &mdash; Two other commercially available medications,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"       sodium oxybate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/63/6133?source=see_link\">",
"       nabilone",
"      </a>",
"      , have shown some benefit both for pain and for sleep but require further study before being used routinely for fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/49-52\">",
"       49-52",
"      </a>",
"      ]; neither should be used outside of approved clinical trials. Nabilone, a synthetic cannabinoid, is a controlled substance in the United States.",
"      <br/>",
"      <br/>",
"      The sedative sodium oxybate is a commercially available preparation of naturally occurring gamma hydroxybutyrate (GHB), a potent sedative. Several randomized trials demonstrated significantly improved fibromyalgia symptoms with this drug [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. The effects of GHB in fibromyalgia were similar to those seen in narcolepsy treatment trials; it improved sleep of FM patients, increased slow-wave sleep duration as well as delta power, and reduced frequent night-time awakenings. Furthermore, pain and fatigue were consistently reduced with nightly GHB over time. Despite its proven efficacy, GHB did not receive FDA approval in the United States for the management of FM in 2010, mostly because of concerns about potential for abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/64\">",
"       64",
"      </a>",
"      ]. Other hydroxytryptamine receptor antagonists, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      , which is administered intravenously, have been studied in other countries [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of narcolepsy\", section on 'Sodium oxybate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transcranial stimulation &mdash; Transcranial direct current stimulation (tDCS) was assessed for pain-relieving effects in a study that randomly assigned 32 patients with fibromyalgia to receive sham stimulation, real tDCS with the anode centered over the primary motor cortex, or stimulation of the dorsolateral prefrontal cortex [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/59\">",
"       59",
"      </a>",
"      ]. Direct current stimulation consisted of 2 mA for 20 minutes on five consecutive days with the anode placed on the scalp over the appropriate brain region. The change in pain was significantly greater in those who received real tDCS to the motor cortex than in the groups receiving sham or dorsolateral prefrontal cortex stimulation. Further study is warranted to assess the efficacy and safety of tDCS. Transcranial magnetic stimulation (TMS) of the left prefrontal cortex, administered in a two-week randomized trial involving 20 patients with fibromyalgia, significantly reduced symptoms of pain from the level at baseline compared with sham TMS (mean reduction of 29 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/41/5786/abstract/61\">",
"       61",
"      </a>",
"      ]. Symptoms of depression also improved. Further study is required to assess the efficacy and safety of TMS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=see_link&amp;anchor=H29061775#H29061775\">",
"       \"Unipolar depression in adults: Overview of neuromodulation procedures\", section on 'Transcranial direct current stimulation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16682?source=see_link\">",
"       \"Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22301621\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of fibromyalgia is directed at reducing the major symptoms of this disorder, including chronic widespread pain, fatigue, insomnia, and cognitive dysfunction. In patients with continued symptoms despite initial nonpharmacologic measures and treatment with single drugs at the maximum tolerated dose, we continue the use of both nonpharmacologic and pharmacologic treatment measures, and we modify or add specific interventions depending upon the symptoms, patient preferences regarding the types of therapies, available resources, and expertise. (See",
"      <a class=\"local\" href=\"#H281622868\">",
"       'Overview of treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H351008102\">",
"       'Patients not responsive to initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using combination drug therapy in most patients unresponsive to monotherapy, rather than switching to or adding analgesics and rather than continuing monotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Medication selection should be guided by the symptoms that most affect the patient. We combine drugs of different classes (eg, a serotonin and norepinephrine reuptake inhibitor [SNRI] such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      in the morning, with a low dose of an anticonvulsant, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , in the evening; or a low dose of a selective serotonin reuptake inhibitor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , or an SNRI, in the morning with a low dose of tricyclic antidepressant, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      , in the evening) to take advantage of multiple mechanisms of action for reducing pain and to target different symptoms. (See",
"      <a class=\"local\" href=\"#H22299532\">",
"       'Combination drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have had difficulty achieving a sufficient level of low-impact aerobic exercise, we encourage participation in a supervised physical medicine and rehabilitation program. We refer patients with continued difficulties with exercise or physical functioning to a physiatrist for further evaluation and for assistance in management. (See",
"      <a class=\"local\" href=\"#H351009661\">",
"       'Exercise and physical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients whose symptoms do not respond adequately to initial therapies, we suggest referral for psychological interventions, such as cognitive behavioral therapy (CBT) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); the specific interventions should be individualized based upon patient preference and available resources. Other psychological measures that may be beneficial include mindfulness-based treatments, relaxation, biofeedback, behavioral treatments, and educational interventions. (See",
"      <a class=\"local\" href=\"#H22299539\">",
"       'Psychological therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should generally be multidisciplinary and should be individualized with attention to the patient&rsquo;s particular symptoms. In patients who have not responded adequately to initial therapies, we advise consultation with specialists in rheumatology, physiatry, psychiatry, neuropsychology, or sleep medicine for further evaluation and for assistance in management, depending upon the expertise of the treating clinician and upon the patient&rsquo;s symptoms and comorbidities. Alternatively, multidisciplinary treatment and specialist consultation can be facilitated by multidisciplinary treatment programs. (See",
"      <a class=\"local\" href=\"#H351008147\">",
"       'Consultation and referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H281624293\">",
"       'Multidisciplinary treatment programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several approaches may be tried in patients who do not respond to the more well-substantiated nonpharmacologic and pharmacologic therapies. Most of these additional approaches are supported by more limited evidence, including analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      ), antiinflammatory drugs, alternative antidepressants, and complementary and alternative therapies (eg, tai chi or yoga). (See",
"      <a class=\"local\" href=\"#H22300507\">",
"       'Analgesic and antiinflammatory drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22300536\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22300584\">",
"       'Complementary and alternative therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that opioids are effective in the treatment of fibromyalgia, and studies have suggested possible adverse effects. In patients who have not responded to multidisciplinary individualized nonpharmacologic and pharmacologic therapy, we favor the use of pain clinics that utilize a multidisciplinary approach to fibromyalgia therapy rather than pain clinics that lack such interest and expertise. (See",
"      <a class=\"local\" href=\"#H22300514\">",
"       'Analgesics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H281624300\">",
"       'Role of pain clinics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/1\">",
"      Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am 2009; 35:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/2\">",
"      Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/3\">",
"      Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/4\">",
"      Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol 2009; 5:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/5\">",
"      Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 2011; 7:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/6\">",
"      Calandre EP, Rico-Villademoros F, Rodr&iacute;guez-L&oacute;pez CM. Monotherapy or combination therapy for fibromyalgia treatment? Curr Rheumatol Rep 2012; 14:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/7\">",
"      Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011; 41:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/8\">",
"      Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/9\">",
"      van Koulil S, van Lankveld W, Kraaimaat FW, et al. Tailored cognitive-behavioral therapy and exercise training for high-risk patients with fibromyalgia. Arthritis Care Res (Hoboken) 2010; 62:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/10\">",
"      van Koulil S, Effting M, Kraaimaat FW, et al. Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann Rheum Dis 2007; 66:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/11\">",
"      Glombiewski JA, Sawyer AT, Gutermann J, et al. Psychological treatments for fibromyalgia: a meta-analysis. Pain 2010; 151:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/12\">",
"      White KP, Nielson WR. Cognitive behavioral treatment of fibromyalgia syndrome: a followup assessment. J Rheumatol 1995; 22:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/13\">",
"      Hadhazy VA, Ezzo J, Creamer P, Berman BM. Mind-body therapies for the treatment of fibromyalgia. A systematic review. J Rheumatol 2000; 27:2911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/14\">",
"      Williams DA. Psychological and behavioural therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003; 17:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/15\">",
"      Sephton SE, Salmon P, Weissbecker I, et al. Mindfulness meditation alleviates depressive symptoms in women with fibromyalgia: results of a randomized clinical trial. Arthritis Rheum 2007; 57:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/16\">",
"      Grossman P, Tiefenthaler-Gilmer U, Raysz A, Kesper U. Mindfulness training as an intervention for fibromyalgia: evidence of postintervention and 3-year follow-up benefits in well-being. Psychother Psychosom 2007; 76:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/17\">",
"      Schmidt S, Grossman P, Schwarzer B, et al. Treating fibromyalgia with mindfulness-based stress reduction: results from a 3-armed randomized controlled trial. Pain 2011; 152:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/18\">",
"      Rooks DS, Gautam S, Romeling M, et al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med 2007; 167:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/19\">",
"      H&auml;user W, Bernardy K, U&ccedil;eyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/20\">",
"      H&auml;user W, Bernardy K, U&ccedil;eyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain 2009; 145:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/21\">",
"      Redondo JR, Justo CM, Moraleda FV, et al. Long-term efficacy of therapy in patients with fibromyalgia: a physical exercise-based program and a cognitive-behavioral approach. Arthritis Rheum 2004; 51:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/22\">",
"      Sewitch MJ, Dobkin PL, Bernatsky S, et al. Medication non-adherence in women with fibromyalgia. Rheumatology (Oxford) 2004; 43:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/23\">",
"      Ge HY, Nie H, Madeleine P, et al. Contribution of the local and referred pain from active myofascial trigger points in fibromyalgia syndrome. Pain 2009; 147:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/24\">",
"      Affaitati G, Costantini R, Fabrizio A, et al. Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 2011; 15:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/25\">",
"      Offenb&auml;cher M, Stucki G. Physical therapy in the treatment of fibromyalgia. Scand J Rheumatol Suppl 2000; 113:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/26\">",
"      Bennett RM, Burckhardt CS, Clark SR, et al. Group treatment of fibromyalgia: a 6 month outpatient program. J Rheumatol 1996; 23:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/27\">",
"      H&auml;user W, Bernardy K, Arnold B, et al. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum 2009; 61:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/28\">",
"      Hooten WM, Townsend CO, Sletten CD, et al. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. Pain Med 2007; 8:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/29\">",
"      Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/30\">",
"      Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003; 114:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/31\">",
"      Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia. Int J Rheum Dis 2011; 14:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/32\">",
"      Fitzcharles MA, Ste-Marie PA, Gamsa A, et al. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med 2011; 124:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/33\">",
"      Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986; 29:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/34\">",
"      Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985; 12:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/35\">",
"      Russell IJ, Fletcher EM, Michalek JE, et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 1991; 34:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/36\">",
"      Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/37\">",
"      Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/38\">",
"      Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. Eur J Pain 2000; 4:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/39\">",
"      N&oslash;rregaard J, Volkmann H, Danneskiold-Sams&oslash;e B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/40\">",
"      Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 2007; 120:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/41\">",
"      Nishikai M, Akiya K. Fluvoxamine therapy for fibromyalgia. J Rheumatol 2003; 30:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/42\">",
"      Wang C, Schmid CH, Rones R, et al. A randomized trial of tai chi for fibromyalgia. N Engl J Med 2010; 363:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/43\">",
"      Martin DP, Sletten CD, Williams BA, Berger IH. Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial. Mayo Clin Proc 2006; 81:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/44\">",
"      Mayhew E, Ernst E. Acupuncture for fibromyalgia--a systematic review of randomized clinical trials. Rheumatology (Oxford) 2007; 46:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/45\">",
"      De Silva V, El-Metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. Rheumatology (Oxford) 2010; 49:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/46\">",
"      Carson JW, Carson KM, Jones KD, et al. A pilot randomized controlled trial of the Yoga of Awareness program in the management of fibromyalgia. Pain 2010; 151:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/47\">",
"      Langhorst J, Klose P, Musial F, et al. Efficacy of acupuncture in fibromyalgia syndrome--a systematic review with a meta-analysis of controlled clinical trials. Rheumatology (Oxford) 2010; 49:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/48\">",
"      Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005; 52:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/49\">",
"      Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003; 30:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/50\">",
"      Russell IJ, Perkins AT, Michalek JE, Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009; 60:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/51\">",
"      Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/52\">",
"      Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/53\">",
"      Vaer&oslash;y H, Abrahamsen A, F&oslash;rre O, K&aring;ss E. Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Clin Rheumatol 1989; 8:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/54\">",
"      Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998; 104:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/55\">",
"      Finckh A, Berner IC, Aubry-Rozier B, So AK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005; 32:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/56\">",
"      Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990; 18:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/57\">",
"      M&uuml;ller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol Suppl 2000; 113:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/58\">",
"      Sp&auml;th M, Stratz T, Neeck G, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004; 33:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/59\">",
"      Fregni F, Gimenes R, Valle AC, et al. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum 2006; 54:3988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/60\">",
"      Distler O, Eich W, Dokoupilova E, et al. Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2010; 62:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/61\">",
"      Short EB, Borckardt JJ, Anderson BS, et al. Ten sessions of adjunctive left prefrontal rTMS significantly reduces fibromyalgia pain: a randomized, controlled pilot study. Pain 2011; 152:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/62\">",
"      Arnold LM, Chatamra K, Hirsch I, Stoker M. Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2010; 32:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/63\">",
"      Russell IJ, Holman AJ, Swick TJ, et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain 2011; 152:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/64\">",
"      Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother 2011; 12:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/41/5786/abstract/65\">",
"      Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain 2011; 15:509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16856 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5786=[""].join("\n");
var outline_f5_41_5786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22301621\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22299051\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281622868\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351008095\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351008102\">",
"      Patients not responsive to initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22299532\">",
"      COMBINATION DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351009661\">",
"      EXERCISE AND PHYSICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22299539\">",
"      PSYCHOLOGICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112654338\">",
"      FACTORS LIMITING TREATMENT EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112654434\">",
"      Nonadherence to treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112654470\">",
"      Treating peripheral pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351008147\">",
"      CONSULTATION AND REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281624293\">",
"      Multidisciplinary treatment programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281624300\">",
"      Role of pain clinics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22300452\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22300507\">",
"      Analgesic and antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22300514\">",
"      - Analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22300521\">",
"      - Antiinflammatory medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22300536\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22300584\">",
"      Complementary and alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22300591\">",
"      - Tai chi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22300598\">",
"      - Yoga",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22300605\">",
"      - Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5085033\">",
"      Injection therapies and other physical measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22300619\">",
"      INVESTIGATIONAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22301621\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/16856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/16856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24427\" title=\"table 1\">",
"      Stepwise FM therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35608?source=related_link\">",
"      Differential diagnosis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=related_link\">",
"      Initial treatment of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=related_link\">",
"      Overview of soft tissue rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=related_link\">",
"      Pathogenesis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=related_link\">",
"      Treatment of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=related_link\">",
"      Unipolar depression in adults: Overview of neuromodulation procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16682?source=related_link\">",
"      Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_41_5787="Echo views for valves";
var content_f5_41_5787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used views to evaluate cardiac valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Valve",
"       </td>",
"       <td class=\"subtitle1\">",
"        View",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic valve",
"       </td>",
"       <td>",
"        PLA, PSA (base), apical long axis, apical 5-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve",
"       </td>",
"       <td>",
"        PLA, PSA (mid), apical long axis, subcostal 4-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricuspid valve",
"       </td>",
"       <td>",
"        Parasternal RV inflow, PSA (mid), apical 4-chamber, apical long axis, subcostal 4-chamber, subcostal short axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonic",
"valve",
"       </td>",
"       <td>",
"        Parasternal RV outflow, PSA (base), subcostal short axis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PLA: parasternal long axis; PSA: parasternal short axis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5787=[""].join("\n");
var outline_f5_41_5787=null;
var title_f5_41_5788="Neuromuscular and chest wall conditions managed with NPPV";
var content_f5_41_5788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neuromuscular and chest wall conditions that may be managed with noninvasive alternatives to tracheostomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Myopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Muscular dystrophies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dystrophinopathies - Duchenne and Becker dystrophies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Limb-girdle, Emery-Dreifuss, facioscapulohumeral, congenital, autosomal recessive, and myotonic muscular dystrophies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital and metabolic myopathies (eg, acid maltase deficiency, alpha glucosidase deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory myopathies (eg, polymyositis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diseases of myoneural junction (eg, myasthenia gravis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurological disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal muscular atrophies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motor neuron diseases (eg, amyotrophic lateral sclerosis, poliomyelitis, postpoliomyelitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary sensory motor neuropathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropathies (eg, phrenic neuropathies, Guillain-Barr&eacute; syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic tetraplegia (eg, pancuronium bromide, botulism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traumatic and other myelopathies (eg, spinal cord injury)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity hypoventilation syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital hypoventilation syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Skeletal pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kyphoscoliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteogenesis imperfecta",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5788=[""].join("\n");
var outline_f5_41_5788=null;
var title_f5_41_5789="Hypoglycemia and HbA1c";
var content_f5_41_5789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increased risk of hypoglycemia with strict glycemic control",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Diabetes Control and Complications Trial, there was a progressive increase in the incidence of severe hypoglycemic episodes (per 100 patient-years) at lower attained hemoglobin A1c values during intensive insulin therapy in patients with type 1 diabetes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Diabetes Control and Complications Trial Research Group, N Engl J Med 1993; 329:977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5789=[""].join("\n");
var outline_f5_41_5789=null;
var title_f5_41_5790="FEV1 growth curves";
var content_f5_41_5790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 growth curves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Growth curves FEV",
"    <sub>",
"     1",
"    </sub>",
"    for healthy boys showing increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    with increasing height.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Wang X, Dockery DW, Wypij D, et al. Pediatr Pulmonol 1993; 15:75.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5790=[""].join("\n");
var outline_f5_41_5790=null;
var title_f5_41_5791="Hunter syndrome papular rash";
var content_f5_41_5791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular rash in a patient with mucopolysaccharidosis type II (MPS II, Hunter syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papular rash across the shoulders of a six-year-old boy with MPS II, Hunter syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_41_5791=[""].join("\n");
var outline_f5_41_5791=null;
